EUROPEAN HEMATOLOGY ASSOCIATION

18th Congress of EHA

 

13-16 June 2013 STOCKHOLM
Close
N. Poster
Poster title
Applicant name
Status
  3-P NOVEL COPY NUMBER ALTERATIONS IN INFANTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (T-ALL) Marcela B. Mansur Received Received
  6-P ACUTE LYMPHOBLASTIC LEUKEMIA RECOGNITION BY NATURAL KILLER CELLS: CLINICAL AND THERAPEUTIC IMPLICATIONS Nadia Peragine Received Received
  7-P K-RASG12D-initiated T-ALL development in mice is accompanied by loss of the wild-type Kras allele Anna Staffas Received Received
  8-P FREQUENCY AND PROGNOSTIC SIGNIFICANCE OF COPY NUMBER ALTERATIONS (CNA) IN HIGH-RISK B-LINEAGE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS ENROLLED IN RISK-ADAPTED PROTOCOLS Jordi Ribera Received Received
  9-P P38ALPHA/BETA INHIBITION PREVENTS ALL PROLIFERATION IN VIVO Denis Schewe Received Received
  12-P ANALYSIS OF CRLF2 EXPRESSION IN A COHORT OF 91 NEWLY DIAGNOSED ADULT PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: CORRELATION WITH CLINICO-BIOLOGICAL FEATURES AND OUTCOME Fulvia Brugnoletti Received Received
  13-P A CLINICALLY RELEVANT POPULATION OF LEUKEMIC CD34CD19CD58- CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA Yuan Kong Received Received
  17-P ETV6/RUNX1 TRANSCRIPT IS A POTENTIAL TARGET OF RNA-BINDING PROTEIN IGF2BP1 Mindaugas Stoskus Received Received
  18-P SNP ARRAY ANALYSIS OF ADULT ALL: A POPULATION BASED STUDY OF LITHUANIAN PATIENTS Vaidas Dirse Received Received
  22-P PML/RAR-ALPHA INHIBITS PTEN EXPRESSION IN HEMATOPOIETIC CELLS BY COMPETING WITH PU.1 TRANSCRIPTIONAL ACTIVITY Nelida Ines Ngguera Received Received
  26-P THE GENE SIGNATURE IN C/EBPA DYSFUNCTIONAL AML PREDICTS RESPONSIVENESS TO HDAC INHIBITORS Meritxell Alberich Jorda Received Received
  29-P THE EFFECT OF ARA-C TREATMENT ON HEMATOPOIETIC STEM CELL EXPANSION AND LEUKEMOGENESIS IN A MOUSE MODEL OF CEBPA MUTANT ACUTE MYELOID LEUKEMIA monica cimino Received Received
  32-P C/EBPA REGULATES CXCR4 EXPRESSION IN ACUTE MYELOID LEUKEMIA Yuan-Yeh Kuo Received Received
  33-P COMBINED INHIBITION OF C-KIT AND PI3K/MTOR SIGNALLING HAS SYNERGISTIC ACTIVITY IN C-KIT MUTANT AML Steven Tinsley Received Received
  34-P THE FUSION GENE NUP98-HOXA9 AS A MODEL FOR LEUKEMOGENESIS: EXPLORING ITS MOLECULAR MECHANISMS AND FUNCTIONAL EFFECTS ANA RIO-MACHIN Received Received
  35-P ACID CERAMIDASE PROMOTES ACUTE MYELOID LEUKEMIA SURVIVAL THROUGH MCL-1 UPREGULATION Su-Fern Tan Received Received
  36-P ANTILEUKEMIC EFFECT OF PI3K-MTOR INHIBITORS IN ACUTE MYELOID LEUKEMIA- GENE EXPRESSION PROFILES REVEAL CDC25B EXPRESSION AS DETERMINATE OF PHARMACOLOGICAL EFFECT Hkon Reikvam Received Received
  37-P L-ASPARAGINASE ALTERS TRANSCRIPTION AND TRANSLATION OF GENES INVOLVED IN METABOLISM IN MYELOID LEUKEMIA Sung Ah Jun Received Received
  38-P THE TYROSINE KINASE CSK ASSOCIATES WITH FLT3 AND KIT RECEPTORS AND REGULATES DOWNSTREAM SIGNALING IN ACUTE MYELOID LEUKEMIA Julhash Kazi Received Received
  39-P WHOLE GENOME AND TARGETED BISULFITE SEQUENCING REVEALS 3 DNA METHYLATION CLUSTERS AND NEW BIOLOGICALLY RELEVANT HYPERMETHYLATED GENES IN AML PATIENTS Hana Hajkova Received Received
  40-P EXPRESSION OF THE SPLICE VARIANT NPM1-R2 HAS STRONGER PROGNOSTIC VALUE THAN NPM1 MUTATIONAL STATUS IN ACUTE MYELOID LEUKEMIA Malgorzata Zajac Received Received
  49-P EX VIVO PHARMACOLOGICAL EVALUATION OF 16 DRUGS IN 60 ACUTE MYELOID LEUKEMIA PATIENTS USING WHOLE BONE MARROW SAMPLES ANALYZED BY AUTOMATED FLOW CYTOMETRY Belén Liébana Received Received
  50-P SYSTEMATIC REVIEW AND META-ANALYSIS OF ANTI-CD33 ANTIBODY TREATMENT IN AML GEMTUZUMAB OZOGAMACIN HAS ANTI-LEUKAEMIC EFFICACY Ching Loke Received Received
  51-P RISK-ADAPTED TRANSPLANT SELECTION ATTENUATES THE NEGATIVE PROGNOSTIC ROLE OF MINIMAL RESIDUAL DISEASE AND GENETIC HIGH RISK FEATURES Francesco Buccisano Received Received
  53-P ELACYTARABINE / IDARUBICIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO FAILED CYTARABINE BASED INDUCTION, AND EVALUATION OF THE IMPACT OF THE TRANSPORTER HENT1 ON RESPONSE; RESULTS OF A PHASE II STUDY Malin Johansen Received Received
  56-P PATTERNS OF RELAPSE IN 169 PATIENTS TREATED WITH ORAL ARSENIC TRIOXIDE DURING INDUCTION AND/OR MAINTENANCE: A 12-YEAR EXPERIENCE Harinder Gill Received Received
  57-P SURVIVAL IMPACT OF COMPLEX AND MONOSOMAL KARYOTYPE AND LOSS OF CHROMOSOMES 5, 7 AND 17 IN OLDER PATIENTS WITH AML. FIRST EVALUATION OF CYTOGENETIC DATA FROM THE POPULATION BASED SWEDISH AML REGISTRY Vladimir Lazarevic Received Received
  58-P PATIENTS WITH LATE RELAPSE OF ACUTE MYELOID LEUKEMIA HAVE A HIGH RATE OF DURABLE SECOND COMPLETE REMISSIONS WHEN TREATED WITH CHEMOTHERAPY ONLY sa Derolf Received Received
  59-P SURVIVAL IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN GERMANY AND THE UNITED STATES: UNEXPLAINED DIFFERENCES IN SURVIVAL IN YOUNG ADULTS Dianne Pulte Received Received
  61-P LOW- DOSE CHEMOTHERAPY AND DIFFERENTIATING AGENTS AS POST- REMISSION MAINTENANCE PROLONGED DISEASE- FREE AND OVERALL SURVIVAL IN A CASE-CONTROL RETROSPECTIVE STUDY ON POOR PROGNOSIS AML/MDS PATIENTS Crisà Elena Received Received
  62-P A STUDY OF ELACYTARABINE IN RELAPSED OR REFRACTORY AML EVALUATING CARDIAC SAFETY AND PHARMACOKINETIC PROPERTIES Malin Johansen Received Received
  63-P MULTI-LINEAGE DYSPLASIA AS ASSESSED BY IMMUNO-PHENOTYPE HAS NO IMPACT ON OUTCOME OF ACUTE MYELOID LEUKEMIA WITH MUTATED NUCLEOPHOSMIN (NPM1) Francesco Mannelli Received Received
  65-P MEDIUM-SIZED FLT3 INTERNAL TANDEM DUPLICATIONS CONFER WORSE PROGNOSIS, THAN SHORT AND LONG DUPLICATIONS Magdalena Koszarska Received Received
  67-P THERAPY-RELATED MYELOID NEOPLASMS: REPORT OF THE ITALIAN NETWORK ON SECONDARY LEUKEMIAS LUANA FIANCHI Received Received
  68-P AZACITIDINE FOR RELAPSE TREATMENT IN MYELOID MALIGNANCIES FOLLOWING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION Benoit Tessoulin Received Received
  69-P MONITORING MINIMAL RESIDUAL DISEASE IN NPM-1 MUTATED ACUTE MYELOID LEUKEMIA. PRELIMINARY RESULTS AT A SINGLE INSTITUTION Chiara Pagani Received Received
  70-P THE PROGNOSTIC IMPACT OF ADDITIONAL KARYOTYPIC ABNORMALITIES IN T(8;21) ACUTE MYELOID LEUKEMIA Zhentang Lao Received Received
  71-P BAALC GENE EXPRESSION REDUCTION DURING INDUCTION PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA vanessa ponziani Received Received
  74-P SUCCESSFUL SALVAGE TREATMENT WITH CLOFARABINE AND CYTARABINE (ARA-C) IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA alessandra malato Received Received
  75-P ACHIEVING BONE MARROW CLL MINIMAL RESIDUAL DISEASE-FREE STATUS WITH FIRST-LINE FCR IS ASSOCIATED WITH IMPROVED PFS AND CAN BE CONSIDERED A PRIMARY TREATMENT OBJECTIVE PAOLO STRATI Received Received
  76-P DEVELOPMENT OF A COMPREHENSIVE PROGNOSTIC INDEX PATIENTS WITH CLL Natali Pflug Received Received
  78-P CHRONIC LYMPHOCYTIC LEUKEMIA CELLS FROM PAIRED LYMPH NODE AND PERIPHERAL BLOOD SHOW A DIFFERENT PATTERN OF COPY NUMBER ABERRATIONS Silvia Bonina Received Received
  80-P A HIGH NUMBER OF LOSSES IN 11Q CHROMOSOME IS ASSOCIATED WITH SHORT TIME TO FIRST TREATMENT (TFT) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) JOSE-ANGEL HERNANDEZ Received Received
  81-P NOTCH1 MUTATED IGHV UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CONSTITUTIVELY OVEREXPRESSED NUCLEOPHOSMIN-1 AND RIBOSOME-ASSOCIATED COMPONENTS Michele Dal Bo Received Received
  82-P CLL: DIFFERENT AGES, DIFFERENT ANTIGEN RECEPTOR PROFILES PANAGIOTIS BALIAKAS Received Received
  83-P DETECTION OF TP53 DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA BY AN IN VITRO FUNCTIONAL ASSAY BASED ON TP53 ACTIVATION BY THE NON-GENOTOXIC DRUG NUTLIN-3: A PROPOSAL FOR CLINICAL APPLICATION Federico Pozzo Received Received
  85-P SEQUENTIAL MRD ANALYSIS IN CLL DEMONSTRATES EXPONENTIAL EXPANSION WITH A PATTERN THAT CANNOT BE PREDICTED FROM PRE-TREATMENT DOUBLING TIME. Andy Rawstron Received Received
  87-P UNRAVELING THE HETEROGENEITY OF T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) Anton W. Langerak Received Received
  88-P EPIGENETIC INACTIVATION OF MIR-34B/C IN ADDITION TO MIR-34A AND DAPK1 IN CHRONIC LYMPHOCYTIC LEUKEMIA Luqian WANG Received Received
  91-P BIALLELIC LOSSES OF 13Q DO NOT CONFER A POORER OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF 627 PATIENTS WITH ISOLATED 13Q DELETION. Anna Puiggros Received Received
  92-P A HIGH SENSITIVITY METHOD REVEALED A TWOFOLD-INCREASED INCIDENCE OF NOTCH1 MUTATION WITH ADVERSE PROGNOSTIC IMPACT IN CHRONIC LYMPHOCYTIC LEUKAEMIA paolo sportoletti Received Received
  94-P NOVEL ASSAY FOR THE IDENTIFICATION OF NOTCH1 PEST DOMAIN MUTATIONS USING FRAGMENT ANALYSIS AND ALLELE SPECIFIC PCR Paulo Campregher Received Received
  95-P LONG-LASTING RESPONSES TO LENALIDOMIDE AS INITIAL THERAPY OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PAOLO STRATI Received Received
  96-P LOW-DOSE FCR IN ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP Luká Smolej Received Received
  97-P PLATINUM AND HIGH-DOSE CYTARABINE-BASED CHEMOTHERAPY IN ULTRA HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTERS SYNDROME: RESULTS OF A RETROSPECTIVE MULTICENTER STUDY Eric DUROT Received Received
  99-P TOXICITY AND RESPONSE BY COMORBIDITY AND AGE IN A RANDOMIZED STUDY OF ORAL FLUDARABINE AND CYCLOPHOSPHAMIDE WITH RITUXIMAB FIRST-LINE THERAPY OF FIT ELDERLY WITH CHRONIC LYMPHOCYTIC LEUKAEMIA Stephen Mulligan Received Received
  101-P PRELIMINARY RESULTS FROM A SURVEY OF REAL-LIFE FIRST LINE THERAPY OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE UK Tony Todd Received Received
  103-P INCREASED EXPRESSION OF THE EZH2 METHYLTRANSFERASE AND EVIDENCE OF FUNCTIONALITY IN CLL SUBGOUPS WITH AGGRESSIVE CLINICOBIOLOGICAL PROFILES Nikos Papakonstantinou Received Received
  104-P OUTCOMES OF PATIENTS WITH FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) A POPULATION-BASED STUDY FROM A WELL-DEFINED GEOGRAPHIC REGION Sandra Eketorp Sylvan Received Received
  105-P PROLONGED CYTOPENIA RELATED TO FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA PAOLO STRATI Received Received
  106-P FRONTLINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH DELETION 17P PAOLO STRATI Received Received
  108-P UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA. Miguel Piris-Villaespesa Received Received
  110-P THE PROGNOSTIC VALUE OF THE NUMBER OF CELLS WITH A DELETION OF 13Q14 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Ekaterina Zotina Received Received
  113-P IMATINIB OR DASATINIB TREATMENT OF CHRONIC MYELOID LEUKEMIA REDUCES CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS AND INCREASES THEIR CD40 EXPRESSION Stina Sderlund Received Received
  114-P THE AXIS SHP-1/SHP-2 MODULATES VEGFR2 SIGNALING IN CML CELL LINES: VEGFR2 DEREGULATION MAY BE IMPLICATED IN IMATINIB (IMA) RESISTANCE Nicola Esposito Received Received
  115-P SYNERGY BETWEEN JAK INHIBITOR RUXOLITINIB AND TYROSINE KINASE INHIBITORS (TKIS) TO OVERCOME DRUG RESISTANCE RELATED TO BONE MARROW (BM) STROMA MICROENVIRONMENT IN CHRONIC MYELOID LEUKEMIA (CML) Concetta Quintarelli Received Received
  116-P CHRONIC MYELOID LEUKEMIA WITH VARIANT T(9;22) REVEALS A DIFFERENT SIGNATURE FROM CASES WITH CLASSIC TRANSLOCATION. Francesco Albano Received Received
  118-P REDUCED EXPRESSION OF CHIBBY IS A COMPONENT OF BETA-CATENIN ACTIVATION IN CHRONIC MYELOID LEUKEMIA STEM CELLS Elisa Leo Received Received
  119-P DIFFERENTIAL ACTIVATION OF MTOR KINASE IN CHRONIC AND BLASTIC PHASE OF CHRONIC MYELOGENOUS LEUKEMIA Tomasz Stoklosa Received Received
  120-P MYELOID-DERIVED SUPPRESSOR CELLS ARE INCREASED IN CHRONIC MYELOID LEUKEMIA AND EXERT IMMUNE SUPPRESSIVE ACTIVITY Cesarina Giallongo Received Received
  121-P CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS Sung-Eun Lee Received Received
  122-P DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN REVEALS A FREQUENCY OF 35INS INSERTION/TRUNCATION HIGHER THAN EXPECTED Caterina De Benedittis Received Received
  124-P A NEW NON CANONICAL ROLE OF IKB ALPHA IN CHRONIC MYELOID LEUKEMIA PATHOGENESIS Cristina Panuzzo Received Received
  125-P L-AMINO ACID OXIDASE ISOLATED FROM BOTHROPS PIRAJAI INDUCES APOPTOSIS IN BCR-ABL POSITIVE CELLS AND POTENTIATES IMATINIB MESYLATE EFFECT sandra burin Received Received
  126-P IL-2, IL-12 AND IL-15 PREVENT REACTIVE OXYGEN SPECIES ACCUMULATION ON NATURAL KILLER CELLS FROM CHRONIC MYELOID LEUKEMIA PATIENTS FOLLOWING INTERFERON-ALPHA, IMATINIB AND DASATINIB THERAPY Paulo Rodrigues Santos Received Received
  127-P EFFECT OF NILOTINIB ON THE FUNCTION OF CAROTID ARTERY ENDOTHELIAL CELLS mr Gkmen Sevindik Received Received
  128-P STANDARDIZATION OF MRD DETECTION IN CML BY USE OF A PEER GROUP CONVERSION FACTOR Els Dumoulin Received Received
  129-P BIOLOGICAL CHARACTERISTICS AND DYNAMICS OF BCR-ABL1 MULTIPLE MUTATIONS IN TYROSINE KINASE INHIBITOR RESISTANT CML Soohyun Kim Received Received
  131-P 10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML) CLAIRE LUCAS Received Received
  132-P IMPACT OF DRUG TRANSPORTER ABCG2 HAPLOTYPES IN MOLECULAR RESPONSE OF CML PATIENTS IS MODULATED BY IMATINIB DAILY DOSE delord marc Received Received
  135-P FIFTEEN-MONTH UPDATE OF A PHASE II TRIAL OF THE COMBINATION OF PEGYLATED INTERFERON ALPHA2ANILOTINIB AS FIRST LINE THERAPY FOR NEWLY DIAGNOSED CHRONIC PHASE CML PATIENTS Franck Nicolini Received Received
  142-P HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA: RESULTS OF A GERMAN CROSS-SECTIONAL STUDY IN PATIENTS PREVIOUSLY REGISTERED IN PROSPECTIVE, CONTROLLED CLINICAL TRIALS Susanne Sauele Received Received
  144-P DISCONTINUATION OF BCR-ABL1 TYROSINE KINASE INHIBITOR IN CML PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE FOR AT LEAST 1 YEAR: INCLUDING UPDATED DATA FROM KIDS STUDY Yun jeong Oh Received Received
  146-P EFFICACY OF NILOTINIB VERSUS HIGH-DOSE IMATINIB IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE SUBOPTIMAL MOLECULAR RESPONSES TO STANDARD-DOSE IMATINIB: MULTICENTER RE-NICE STUDY Soo Young Choi Received Received
  147-P OCT1 GENETIC VARIANTS ARE ASSOCIATED WITH LONG TERM OUTCOMES IN IMATINIB TREATED CML PATIENTS Maya Koren-Michowitz Received Received
  150-P MECHANISM OF IMPAIRED GLUCOSE METABOLISM DURING NILOTINIB THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA Zdenek Racil Received Received
  152-P FLOW CYTOMETRY EARLY DETECTION OF CD4CD26-CD38 LYMPHOCYTES SUBSET IN LYMPH NODES OF HODGKIN LYMPHOMA Giuseppe Tagariello Received Received
  153-P FIRST-LINE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA FINAL RESULTS OF A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS Michaela Rancea Received Received
  155-P A SIMPLE, ACCESSIBLE NEW TOOL TO DEFINE HIGH RISK PATIENTS IN CLASSICAL HODGKIN LYMPHOMA BASED ON VALIDATION OF PRE-EXISTING BIOMARKERS Paul Greaves Received Received
  158-P ESHAP AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORY HODGKINS LYMPHOMA Jorge Labrador Received Received
  160-P THE LYMPHOCYTIC HISTOPATHOLOGIC SUBTYPES OF HODGKIN LYMPHOMA (HL): CLINICAL PRESENTATION AND LONG-TERM OUTCOME IN A CASE SERIES OF 61 PATIENTS Theodoros Vassilakopoulos Received Received
  161-P LONG TERM RESULTS OF MONOCENTRIC PROSPECTIVE STUDY OF VEBEP PLUS RADIOTHERAPY REGIMEN IN NEWLY DIAGNOSED EARLY-UNFAVORABLE STAGE HODGKIN LYMPHOMA SIMONA PAGLIUCA Received Received
  162-P DEVELOPMENT OF A PROGNOSTIC SCORING SYSTEM FOR PRIMARY REFRACTORY HODGKINS LYMPHOMA TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION Marianna David Received Received
  163-P HETEROGENEOUS MANAGEMENT OF ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA AND INCONSTANT CONFORMITY OF MEDICAL PRACTICE TO CLINICAL GUIDELINES: EXHAUSTIVE COHORT FROM RHNE-ALPES REGION Arthur Dony Received Received
  166-P RECURRENT SETBP1 MUTATIONS IN ATYPICAL CHRONIC MYELOID LEUKEMIA SARA REDAELLI Received Received
  168-P ABERRANT SPLICING DURING ERYTHROID DIFFERENTIATION IN SF3B1 MUTATED SIDEROBLASTIC ANEMIA Simona Conte Received Received
  169-P RESISTANCE TO APOPTOSIS IN HIGH-RISK MYELODYSPLASTIC SYNDROME CAN BE OVERCOME BY PRO-APOPTOTIC DRUG TREATMENT USING ABT-737 Stefanie Jilg Received Received
  173-P A PAIR MONOZYGOTIC TWINS WITH CONCORDANT JUVENILE MYELOMONOCYTIC LEUKEMIA: INSIGHT IN THE COURSE OF THE DISEASE Silvia Bresolin Received Received
  174-P FAMILIAL, NON-ZINC FINGER REGION, GATA2 MUTATED MYELODYSPLASTIC SYNDROME; ASSOCIATED WITH SHORTENED TELOMERE LENGTHS, VIRAL WARTS, PROFOUND MONOCYTE/B/NK CELL DEFICIENCY Mrinal Patnaik Received Received
  175-P EVALUATION OF PRO-SURVIVAL PATHWAYS, INCLUDED AUTOPHAGY, IN HIGH-RISK MDS BONE MARROW AFTER TREATMENT WITH 5-AZACITIDINE TO RESTORE NORMAL HEMATOPOIESIS ALESSANDRA ROMANO Received Received
  177-P FLOW CYTOMETRIC CLASSIFICATION OF 350 TYPE III PNH CLONES IN ITALY: A MULTI-CETRIC STUDY ELISA CANNIZZO Received Received
  178-P CYTOGENETIC CHARACTERIZATION OF CD34 HEMATOPOIETIC PROGENITOR CELLS AND MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROME (MDS) Maria Pimenova Received Received
  179-P POLYMORPHISMS IN GENES INVOLVED IN DNA REPAIR AND FOLATE PATHWAY SIGNIFICANTLY IMPACT ON SURVIVAL IN LOW-RISK, UNTREATED MYELODYSPLASIA. Giuseppe Visani Received Received
  183-P EVALUATION OF A HIGH THROUGHPUT MUTATION-SCREENING STRATEGY IN MYELODYSPLASTIC SYNDROME PATIENTS AND ACUTE MYELOID LEUKEMIA USING TARGETED-GENE ENRICHMENT TECHNOLOGY Mohsen Karimi Arzenani Received Received
  184-P Impact of 5q Breakpoints on Clinical Outcomes in Patients With IPSS Low/Int-1-Risk Myelodysplastic Syndromes (MDS) and Isolated del(5q) Treated With Lenalidomide in the MDS-004 Study Gudrun Ghring Received Received
  185-P PROGNOSTIC IMPACT OF DER(1;7) IN MDS IS DIFFERENT FROM DEL(7Q) Julie Schanz Received Received
  186-P CLINICAL SIGNIFICANCE OF ASXL1 MUTATION IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROME AND ITS STABILITY DURING DISEASE PROGRESSION Tsung Chih Chen Received Received
  188-P HIGH DOSES OF ELTROMBOPAG ARE WELL-TOLERATED IN CONJUNCTION WITH AZACITIDINE AND THE COMBINATION DEMONSTRATES ENCOURAGING ACTIVITY IN PATIENTS WITH MDS AND AML. Michael Dickinson Received Received
  195-P IMPROVED PREDICTIVE PROGNOSTIC POWER OF REVISED-IPSS (IPSS-R) IN A SERIES OF 301 PATIENTS WITH MYELODYSPLASTIC SYNDROME FROM A SINGLE CENTER. Montserrat Arnan Sangerman Received Received
  197-P HIGH LEVELS OF CEREBLON MESSENGER RNA ARE THE CHARACTERISTIC FEATURE OF LOWER RISK MYELODYSPLASTIC SYNDROMES WITH 5Q DELETION AND ARE CONNECTED WITH THE EFFICACY OF LENALIDOMIDE Ota Fuchs Received Received
  199-P MORTALITY BURDEN OF TRANSFUSION DEPENDENCY AND IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. Montserrat Arnan Sangerman Received Received
  200-P NOVEL 3Q26 DELETION BONE MARROW FAILURE SYNDROME IN A NEWBORN RESULTING IN DOMINANT NEGATIVE INTERFERENCE OF HEMATOPOIESIS BY TRUNCATED EVI1/MECOM Lars van der Veken Received Received
  202-P EUROPEAN PATTERN AND IMPACT OF THE USE ERYTHROPOIETIC AGENTS (ESAS)IN LOW AND INT-1 RISK MDS WITH PROPENSITY SCORING TECHNIQUES IN OBSERVATIONAL LONGITUDINAL STUDIES. Hege Garelius Received Received
  204-P ANTI-MYELOMA ACTIVITY OF A NOVEL ALKYLATING AGENT MELPHALAN-FLUFENAMIDE Dharminder Chauhan Received Received
  205-P METABOLOMIC PROFILING IDENTIFIES MECHANISMS REGULATING HYPOXIA-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA. Patricia Maiso Received Received
  206-P GENOMIC CHARACTERIZATION OF THE PUTATIVE MULTIPLE MYELOMA STEM CELLS CLONE REVEALS COPY NUMBER ALTERATIONS (CNAS) POSSIBLY CORRELATED WITH THE ORIGIN OF DISEASE Marina Martello Received Received
  207-P MULTIDIMENSIONAL FLOW CYTOMETRY FOR SENSITIVE EVALUATION OF PATIENTS WITH IGM MGUS OR WALDENSTROMS MACROGLOBULINEMIA AND DIFFERENTIAL DIAGNOSIS WITH OTHER LYMPHOMAS Bruno Paiva Received Received
  208-P IDENTIFICATION OF SERUM MICRORNA PROFILE IN MULTIPLE MYELOMA ASSOCIATED WITH COMPLETE REMISSION AND PROGRESSION AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION Carlos Fernández de Larrea Received Received
  209-P IMPROVED ACCURACY OF DISCRIMINATION BETWEEN IGM MULTIPLE MYELOMA (MM) AND WALDENSTROEMS MACROGLOBULINAEMIA (WM) BY TESTING FOR MYD88 L265P MUTATIONS Wolfgang Willenbacher Received Received
  210-P ABT-199 IS HIGHLY EFFECTIVE AGAINST MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA HARBORING T(11;14) TRANSLOCATION Cyrille Touzeau Received Received
  214-P MULTIDIMENSIONAL FLOW CYTOMETRY IMMUNOPHENOTYPIC QUANTIFICATION AND CHARACTERIZATION OF IN VIVO MESENCHYMAL STEM CELLS IN MGUS AND MULTIPLE MYELOMA Rui Leite Received Received
  216-P AN EGFP IMAGING BASED IN VIVO MODEL FOR STUDYING THE BIOLOGY AND TREATMENT OF MULTIPLE MYELOMA lisha ai Received Received
  217-P IDENTIFICATION OF POTENTIAL DRUG TARGETS WITHIN THE UBIQUITIN PROTEASOME SYSTEM IN MULTIPLE MYELOMA Lisa Crawford Received Received
  218-P MULTIPARAMETER FLOW CYTOMETRY DETECTION OF CLONAL PLASMA CELLS IN THE BONE MARROW OF PATIENTS WITH SOLITARY PLASMACYTOMA DETERMINES THE RISK OF PROGRESSION TO ACTIVE MYELOMA Bruno Paiva Received Received
  219-P CAN IMMUNOPHENOTYPIC CR BE ALSO ACHIEVED IN RELAPSED MULTIPLE MYELOMA PATIENTS? Bruno Paiva Received Received
  220-P MYELOMA PLASMA CELLS ALTER THE BONE MICROENVIRONMENT BY STIMULATING AN INCREASE IN MESENCHYMAL STEM CELL NUMBERS Jacqueline Noll Received Received
  221-P EFFICACY AND SAFETY OF 3 LENALIDOMIDE-BASED COMBINATIONS IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS FROM THE PHASE 3 COMMUNITY BASED EMN01 TRIAL Francesca Gay Received Received
  223-P BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE VERSUS THALIDOMIDE-DEXAMETHASONE PLUS AUTOTRANSPLANTATION FOR MULTIPLE MYELOMA: UPDATED FOLLOW-UP AND OUTCOMES AFTER RELAPSE IN THE PHASE 3 GIMEMA-MMY-3006 TRIAL paola tacchetti Received Received
  226-P MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) Paul Richardson Received Received
  227-P TANDEM AUTOLOGOUS/ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS IN FIRST LINE HIGH RISK MULTIPLE MYELOMA PATIENTS: EVOLVING STRATEGIES WITH THE IMMUNOMODULATING DRUGS Mauricette Michallet Received Received
  231-P BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) IN ELDERLY MM PROGRESSIVE AFTER 1ST LINE THERAPY (IFM 2009-01 TRIAL): PREDICTIVE FACTORS OF DEFAVOURABLE OUTCOME Philippe Rodon Received Received
  235-P A COMPARISON BETWEEN NEXT-GENERATION SEQUENCING AND ASO-QPCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA Hiroyuki Takamatsu Received Received
  241-P IMPACT OF HISTORY OF AUTOIMMUNE DISEASE ON SURVIVAL IN MULTIPLE MYELOMA AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE Ebba Lindqvist Received Received
  242-P LOW RATE OF SECONDARY PRIMARY MALIGNANCIES (SPMS) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH LENALIDOMIDE: FIRST RESULTS FROM THE MRC MM XI TRIAL Annamaria Brioli Received Received
  243-P THERAPY FOLLOWING RELAPSE ON MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) FOLLOWED BY LEN MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EFFICACY AND SAFETY OF SECOND LINE LEN IN MM-015 Meletios Dimopoulos Received Received
  244-P ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE LOW-DOSE DEXAMETHASONE (POM LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Katja Weisel Received Received
  245-P SALVAGE TREATMENT WITH POMALIDOMIDE-CYCLOPHOSPHAMIDE-PREDNISONE PRODUCES SIMILAR OUTCOMES AS COMPARED TO PRIOR THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Alessandra Larocca Received Received
  248-P A MOUSE MODEL FOR HUMAN MYELOFIBROSIS IOANNA TRIVIAI Received Received
  249-P DEREGULATED MIRNAS IN JAK2V617F-NEGATIVE ESSENTIAL THROMBOCYTHEMIA PATIENTS TARGET SOCS FAMILY MEMBERS Beatriz Bellosillo Received Received
  250-P A DIFFERENTIAL CENTROSOME LOCALIZZATION OF WILD TYPE (WT) AND JAK2V617F PROTEIN IN HUMAN LEUKEMIA CELL LINES Biagio De Angelis Received Received
  251-P EVALUATION OF THROMBIN GENERATION POTENTIAL IN POLYCYTHEMIA VERA PATIENTS ENROLLED IN THE CYTO-PV ITALIAN CLINICAL TRIAL Marina Marchetti Received Received
  253-P A TRANSLOCATION T(3 ;13)(Q13 ;Q12) FUSES FLT3 TO A NOVEL PARTNER GENE, GOLGB1, IN A MYELOID/LYMPHOID NEOPLASM WITH EOSINOPHILIA. Estelle TROADEC Received Received
  255-P INCREASED PREVALENCE OF AUTOIMMUNE PHENOMENA IN MYELOFIBROSIS: RELATIONSHIP WITH CLINICAL AND MORPHOLOGICAL CHARACTERISTICS, AND WITH IMMUNOREGULATORY CYTOKINE PATTERNS Francesca Guidotti Received Received
  257-P ALL-TRANS RETINOIC ACID POTENTIATES THE INHIBITORY EFFECTS OF INTERFERON ALPHA (IFN) ON CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN) PROGENITORS IN VITRO. Novella Pugliese Received Received
  258-P SETBP1 OVEREXPRESSION IN CLASSICAL BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS Francesco Albano Received Received
  259-P CUSTOM AMPLICON CAPTURE AND BENCH-TOP HIGH THROUGHPUT SEQUENCING TO SCREEN FOR MUTATIONS ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASMS Gareth Gerrard Received Received
  260-P QUANTITATIVE RT-PCR FOR PDGFR IS USEFUL FOR DIAGNOSIS AND MOLECULAR MONITORING OF PATIENTS WITH PDGFR REARRANGEMENTS TREATED WITH TYROSINE-KINASE INHIBITORS Eric Lippert Received Received
  261-P CHARACTERIZATION OF PLATELET HYPERCOAGULABILITY IN HIGH-HEMATOCRIT POLYCYTHEMIA VERA PATIENTS Marina Marchetti Received Received
  262-P CHARACTERIZATION OF MUTATIONS IN ASXL1, SRSF2, CBL AND JAK2 GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA Laura Palomo Received Received
  263-P ADDITIONAL MUTATIONS TARGETING GENES UNRELATED TO RAS PATHWAY ARE FOUND IN SPORADIC JMML BUT NOT IN SYNDROMIC JMML Aurélie Caye Received Received
  264-P DETECTION OF LEUKEMIA-ASSOCIATED MUTATIONS IN HEMATOLOGICALLY NORMAL ELDERLY INDIVIDUALS Joannah Score Received Received
  265-P THE IDENTIFICATION OF A PSTAT5 GENE SIGNATURE AND ITS MODULATION IN RUXOLITINIB PHARMACODYNAMIC RESPONSE IN HEMATOLOGIC MALIGNANCY Jessica Litvan Received Received
  266-P DO MYELOPROLIFERATIVE NEOPLASMS (MPNS) HAVE STAGES? ANALYSIS OF RELATIONSHIP OF DISEASE DURATION, PROGNOSTIC SCORES, AND SYMPTOMATIC BURDEN OF 1467 MPN PATIENTS Holly Geyer Received Received
  268-P MUTATIONS IN THE RNA SPLICING MACHINERY GENES IN MYELOFIBROTIC TRANSFORMATION OF ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA Beatriz Bellosillo Received Received
  269-P MULTIVARIATE ANALYSIS OF THE ASSOCIATION OF CYTOKINE LEVELS AND REDUCTIONS IN SPLEEN SIZE IN COMFORT-II, A PHASE 3 STUDY COMPARING RUXOLITINIB TO BEST AVAILABLE THERAPY (BAT) Jessica Litvan Received Received
  270-P SPLICEOSOME COMPONENT MUTATIONS AND CYTOGENETIC CORRELATES IN WORLD HEALTH ORGANIZATION (WHO)-DEFINED CHRONIC MYELOMONOCYTIC LEUKEMIA Sameer Parikh Received Received
  271-P ACQUIRED COPY-NEUTRAL LOSS OF HETEROZIGOSITY OF CHROMOSOME 1P AS A MOLECULAR EVENT ASSOCIATED WITH MARROW FIBROSIS IN MPL MUTATED MYELOPROLIFERATIVE NEOPLASMS elisa rumi Received Received
  273-P MYELOPROLIFERATIVE NEOPLASM QUALITY OF LIFE (MPN-QOL) STUDY GROUP: DUAL SERIAL ASSESSMENT STUDIES FOR IMPACT OF STANDARD THERAPEUTIC APPROACHES IN MPN POPULATIONS (MEASURE AND SYMPTOMS TRIALS) Holly Geyer Received Received
  274-P LONG-TERM EFFICACY AND SAFETY OF CLADRIBINE (2-CDA) IN ADULT PATIENTS WITH MAST CELL DISEASE : A FRENCH MULTICENTER STUDY OF 68 PATIENTS stephane BARETE SB Received Received
  275-P CIRCULATING YKL-40 IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) TREATED WITH THE NOVEL HISTONE DEACETYLASE INHIBITOR VORINOSTAT Christen Andersen Received Received
  276-P IMPACT OF HEMATOCRIT ON SYMPTOM BURDEN AMONG POLYCYTHEMIA VERA PATIENTS Robyn Emanuel Received Received
  277-P WHITE BLOOD CELLS COUNT INFLUENCE THE PROGNOSIS OF POLYCYTHEMIA VERA PATIENTS: A SUB-ANALYSIS OF THE CYTO-PV STUDY. RICCARDO CAVAZZINA Received Received
  278-P Safety Overview of Phase 1-2 Studies of Pacritinib, a Non-Myelosuppressive JAK2/FLT3 inhibitor, in Patients with Hematological Malignancies Kristin MacIntosh Received Received
  279-P A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF) Christen Andersen Received Received
  280-P CLINICAL FEATURES OF ESSENTIAL THROMBOCYTHEMIA WITH SPLEEN ENLARGEMENT: THE EXPERIENCE OF LAZIAL GROUP FOR THE STUDY OF SMPC, PH-. Alessandro Andriani Received Received
  284-P DETECTION OF PERIPHERAL BLOOD MONOCLONAL T LYMPHOCYTOSIS AND RISK OF T LYMPHOPROLIFERATIVE DISEASE DEVELOPMENT Giuseppe Tagariello Received Received
  286-P VITAMIN D3 AND LENALIDOMIDE SYNERGIZE TO INDUCE APOPTOSIS IN MANTLE CELL LYMPHOMA VIA DEMETHYLATION OF BIK Carole Brosseau Received Received
  288-P THE HOST GENETIC BACKGROUND MODULATES TREATMENT ACTIVITY AND TOXICITY IN FOLLICULAR LYMPHOMA: FIL-FOLL05 TRIAL Giuseppe Palumbo Received Received
  292-P MYD88 L265P MUTATION IN WALDENSTROM MACROGLOBULINEMIA : INCIDENCE AND FUNCTIONAL STUDY Stephanie Poulain Received Received
  294-P B-CELL REPERTOIRE ANALYSIS OF INDOLENT MCL WITH SPLENIC PRESENTATION : A DISTINCT ONTOGENY FROM CLASSICAL MCL? clémentine sarkozy Received Received
  296-P INFLUENCE OF THE B-CELL RECEPTOR (BCR) SIGNALING PATHWAYS ON CD20 LEVELS IN TUMOR CELLS AND ANTITUMOR ACTIVITY OF ANTI-CD20 MONOCLONAL ANTIBODIES Magdalena Winiarska Received Received
  297-P GENETIC VARIATION IN INTERFERON REGULATORY FACTOR 4 AND INTERLEUKIN 10 GENES, AND THE RISK FOR DIFFUSE LARGE B-CELL LYMPHOMA In-Suk Kim Received Received
  298-P PROGNOSTIC IMPACT OF EZH2 EXPRESSION, H3K27 TRIMETHYLATION AND DNA METHYLATION IN DIFFUSE LARGE B CELL LYMPHOMA Shih-Chiang Lin Received Received
  299-P BMI1 EXERTS ITS ONCOGENIC EFFECTS VIA ENHANCEMENT OF ANTI-APOPTOTIC POTENTIAL IN MANTLE CELL LYMPHOMA kazuaki teshima Received Received
  300-P THE ROLE OF CXCCHEMOKINE IL-8, IL-6 AND CXCR2 RECEPTOR IN LYMPHOPLASMACYTIC LYMPHOMA: CORRELATIONS WITH MICROVASCULAR CHARACTERISTICS AND CLINICAL FEATURES Georgia Levidou Received Received
  301-P HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA Rita Coutinho Received Received
  302-P Upfront allogenic stem cell transplantation in patients with advanced T-cell lymphomas : an intention-to-treat analysis from a single institution Marion Loirat Received Received
  304-P R-CHOP21 VS R-CHOP14 IN 1024 DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS FROM A MULTICENTRE RETROSPECTIVE STUDY OF FONDAZIONE ITALIANA LINFOMI (FIL) Luigi Rigacci Received Received
  305-P SINGLE-AGENT LENALIDOMIDE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMBINED ANALYSIS FROM THE MCL-001, NHL-002, AND NHL-003 STUDIES Marybeth McKenzie Received Received
  307-P INFERIOR OUTCOME OF ELDERLY DLBCL PTS WITH 25-OH VITAMIN D DEFICIENCY TREATED WITH CHOP PLUS RITUXIMAB: RESULTS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP DSHNHL Jrg Thomas Bittenbring Received Received
  310-P PIXANTRONE MONOTHERAPY IN HISTOLOGICALLY CONFIRMED, RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA: POST HOC ANALYSIS FROM A PHASE III TRIAL Arthur Smyth Medina Received Received
  311-P SOX11 CAN BE USED AS A LONGITUDINAL MINIMAL RESIDUAL DISEASE MARKER FOR MANTLE CELL LYMPHOMA Anita Simonsen Received Received
  312-P CONTRIBUTION OF CEREBROSPINAL FLUID SCD19 LEVELS TO THE DETECTION OF CNS LYMPHOMA: IMPACT ON DISEASE OUTCOME Lourdes Martin Martin Received Received
  313-P RITUXIMAB-PECC FOLLOWED BY 90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION IN RELAPSED OR REFRACTORY DLBCL PATIENTS WHO ARE NOT ELIGIBLE FOR OR AFTER ASCT: PRELIMINARY RESULTS FROM A PHASE II HOVON STUDY Pieternella Lugtenburg Received Received
  316-P EFFICACY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN ELDERLY PATIENTS WITH AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: A MULTICENTRIC STUDY. Federica Loscocco Received Received
  317-P THE ROLE OF PET/CT AFTER RITUXIMAB-CHOP (R-CHOP) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): RESPONSE ASSESSMENT, PROGNOSTIC SIGNIFICANCE AND IMPLICATIONS FOR SUBSEQUENT RADIOTHERAPY (RT) Theodoros Vassilakopoulos Received Received
  319-P THE LYMPHOCYTES TO MONOCYTES RATIO IDENTIFIES A PATIENT SUBGROUP AMONG HIGH RISK DLBCL THAT MAY BENEFIT FROM UPFRONT INTENSIVE TREATMENT WITH AUTOGRAFT Anna Maria Barbui Received Received
  321-P NON-INTERVENTIONAL STUDY BE-1ST: FIRST LINE THERAPY WITH BENDAMUSTINE IN ADVANCED INDOLENT NON-HODGKIN LYMPHOMA (NHL) IN TREATMENT ROUTINE Tessa Schliephacke Received Received
  322-P THE PROGNOSTIC ROLE OF EBV IN PERIPHERAL BLOOD OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA Maria Chiara Tisi Received Received
  324-P LYMPHOMAS WITH MYC-TRANSLOCATION OTHER THAN BURKITTS: BAD PROGNOSIS DESPITE SPECIFIC IMMUNOCHEMOTHERAPY FOR BURKITTS LYMPHOMA José Tomás Navarro Received Received
  326-P THE POTENTIAL OF CD127 AS A PROGNOSTIC AND RESIDUAL DISEASE MARKER IN CHRONIC ADULT T CELL LEUKEMIA/LYMPHOMA. Huseini Kagdi Received Received
  327-P EVALUATION OF THE PROGNOSTIC SIGNIFICANCE OF THE BODY MASS INDEX (BMI) IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) RECEIVING RITUXIMAB-CHOP (R-CHOP) OR SIMILAR IMMUNOCHEMOTHERAPY Theodoros Vassilakopoulos Received Received
  328-P AIDS-RELATED LYMPHOMAS (ARL), OUTCOME AND PROGNOSTIC FACTORS TERESA GARRIDO Received Received
  330-P THE USE OF SYSTEMIC THERAPY DOES NOT IMPROVE THE RESULTS OF LOCOREGIONAL TREATMENT IN LIMITED STAGE (I-II) FOLLICULAR LYMPHOMA: STUDY OF 112 PATIENTS. Juan-Manuel Sancho Received Received
  332-P CLINICAL AND MOLECULAR SIGNIFICANCE OF TUMOR NECROSIS IN NEWLY DIAGNOSED PATIENTS WITH HODGKINS LYMHOMA AND DIFFUSE LARGE B CELL LYMPHOMA Ihab Abd el rahman Received Received
  335-P CLINICAL RELEVANCE OF INTERNATIONAL PROGNOSTIC INDEX AS A PREDICTOR FOR VENOUS THROMBOEMBOLISM IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS OF A SINGLE CENTER PROSPECTIVE COHORT STUDY Sung Hee Lim Received Received
  338-P LOWER INCIDENCE OF EBV-POSITIVITY IN ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA: POSSIBLE NEW SUBGROUP OF ELDERLY B-CELL LYMPHOMA Tatsuki Tomikawa Received Received
  341-P UTILITY OF F-18 FDG PET/CT FOR THE DIAGNOSIS AND THERAPEUTIC MANAGEMENT FOR EXTRANODAL NATURAL KILLER (NK)/T CELL LYMPHOMA, NASAL TYPE Bing Xu Received Received
  344-P LONG TERM SURVEY OF 180 PATIENTS TRANSPLANTED AFTER RIC REGIMEN USING THREE DOSES OF ATG: A BELGIAN HEMATOLOGY SOCIETY (BHS) NATIONAL PROSPECTIVE TRIAL Dominique Bron Received Received
  345-P SPECTRUM OF EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Qifa Liu Received Received
  346-P ENTERAL VERSUS PARENTERAL NUTRITIONAL SUPPORT POST ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION RESULTS OF A RANDOMIZED CONTROLLED TRIAL Sarah Andersen Received Received
  347-P COMBINED CMV REPLICATION AND CHRONIC GVHD GENERATE A SIGNIFICANT SYNERGY OF ANTI-LEUKEMIC EFFECT AFTER ALLOGENEIC HSCT IN ACUTE MYELOID LEUKEMIA Ji Eun Jang Received Received
  348-P HUMAN HERPESVIRUS-6 REACTIVATION AND HHV-6 ENCEPHALITIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER, PROSPECTIVE STUDY. Masao Ogata Received Received
  349-P CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN AML PATIENTS WITH CNS DISEASE UNDERGOING ALLOGENIC STEM CELL TRANSPLANTATION- RISK FACTORS AND PROGNOSIS Mrinal Patnaik Received Received
  350-P COMPARISON OF MESENCHYMAL STEM CELLS AND MESENCHYMAL STEM CELLS COMBINED WITH CORD BLOOD FOR TREATMENT OF ENGRAFT FAILURE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE PI Qifa Liu Received Received
  351-P ABCG2 OVEREXPRESSION NEGATIVELY AFFECT OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT IN ACUTE MYELOID LEUKEMIA PATIENTS Mario Tiribelli Received Received
  353-P A LEBANESE-ITALIAN COLLABORATIVE INITIATIVE ON BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ?-THALASSEMIA MAJOR Hussein Abbas Received Received
  356-P CIDOFOVIR AS SECOND LINE THERAPY IN CMV REACTIVATION: CLINICAL AND BIOLOGICAL CORRELATES. Francesca Farina Received Received
  357-P IS IMATINIB MAINTENANCE REQUIRED FOR PATIENTS WITH RELAPSE CHRONIC MYELOID LEUKEMIA POST-TRANSPLANTATION OBTAINING CMR? A PILOT RETROSPECTIVE INVESTIGATION Qifa Liu Received Received
  359-P UNRELATED CORD BLOOD TRANSPLANTATION FOR CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA Changcheng Zheng Received Received
  360-P LENOGRASTIM FROM DAY 7 AND PEGFILGRASTIM ARE EQUALLY EFFECTIVE IN REDUCING TIME TO NEUTROPHIL ENGRAFTMENT, ANTIBIOTIC USE AND INPATIENT STAY IN PATIENTS WITH MYELOMA UNDERGOING AUTOLOGOUS TRANSPLANT Benjamin Bailiff Received Received
  361-P TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE. CARMEN ALBO Received Received
  364-P DONOR AND RECIPIENT STR ANALYSIS BEFORE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: POSSIBLE CORRELATION WITH POST-TRANSPLANT OUTCOME Sabrina Giammarco Received Received
  365-P COMPARISON BETWEEN LONG-TERM AND SHORT-TERM ADMINISTRATION OF ITRACONAZOLE FOR PRIMARY ANTIFUNGAL PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER, RANDOMIZED TRIAL Qifa Liu Received Received
  366-P BENDAMUSTINE, ETOPOSIDE, CYTARABINE AND MELPHALAN (BEEAM) FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCE LONG-LASTING COMPLETE REMISSIONS IN A HIGH PROPORTION OF RESISTANT/RELAPSED LYMPHOMA PATIENTS: 32 MONTHS FOLLOW-UP UPDATE. Alessandro Isidori Received Received
  367-P A CONDITIONING PLATFORM WITH FLUDARABINE, BUSULFAN AND ATG CONDUCTS TO IDENTICAL PROMISING RESULTS IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION FROM BOTH MATCHED AND MISMATCHED UNRELATED DONOR devillier raynier Received Received
  368-P MOLECULAR MONITORING AND STEPWISE PREEMPTIVE THERAPY FOR EPSTEIN-BARR VIRUS VIREMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Qifa Liu Received Received
  371-P REDUCED TOXICITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULTS USING FLUDARABINE, BCNU, MELPHALAN, AND ANTITHYMOCYTE GLOBULIN (FBM-A): OUTCOMES DEPEND ON DISEASE RISK INDEX Jose Leis Received Received
  373-P PREDICTION OF MOBILIZATION FAILURE FOR PRE-EMPTIVE PLERIXAFOR ADMINISTRATION: THE PAMPLONA PROTOCOL AMAYA ZABALZA Received Received
  374-P DOES ALLOGENEIC STEM CELL TRANSPLANTATION OVERCOME THE ADVERSE RISK OF FLT3 POSITIVIVITY IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKAEMIA? Sorcha Ni Loingsigh Received Received
  376-P RITUXIMAB-BASED TREATMENTS FOLLOWED BY ADOPTIVE CELLULAR THERAPIES FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Qifa Liu Received Received
  378-P A GENETIC VARIANT IN THE CD53 INTRON FUNCTIONALLY PREDICTS TRANSPLANT OUTCOMES AFTER HLA-MATCHED UNRELATED BONE MARROW TRANSPLANTATION Akiyoshi Takami Received Received
  379-P RELATIONSHIP BETWEEN INFUSION FEVER FOLLOWING PERIPHERAL BLOOD STEM CELL AND PERI-ENGRAFTMENT SYNDROME IN PEADIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION YAO CHEN Received Received
  381-P STENOTROPHOMONAS MALTOPHILIA INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION -RISK FACTORS AND THERAPEUTIC STRATEGIES- Shiratori Souichi Received Received
  387-P ERYTHROPOIETIN IMPROVES BRAIN DEVELOPMENT IN SHORT-TERM HY0POXIA IN RAT EMBRYO CULTURES Yasemin Altuner Torun Received Received
  388-P DISULFIRAM/COPPER COMPLEX COULD ELIMINATE RAJI CELLS IN VITRO AND VIVO THROUGH ACTIVATION OF OXIDATIVE STRESS AND INHIBITION OF NRF2 AND NF-?B Bing Xu Received Received
  391-P THE SAFETY PROFILE OF DEFERASIROX REMAINS CONSISTENT AS NON-TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS APPROACH THE TARGET LIVER IRON CONCENTRATION OF 3 MG FE/G DW FOR INTERRUPTING CHELATION Germanicus Hansa-Wilkinson Received Received
  392-P PROGNOSTIC CMR PARAMETERS FOR HEART FAILURE AND ARRHYTHMIAS IN A LARGE COHORT OF WELL TREATED THALASSEMIA MAJOR PATIENTS Antonella Meloni Received Received
  393-P IMPACT OF MONITORING WITH LIVER MRI-R2 ON LIVER IRON BURDEN AND DEVELOPMENT OF ENDOCRINOPATHIES: A RETROSPECTIVE AUDIT Stephanie Ko Received Received
  394-P MYOCARDIAL FIBROSIS BY CMR LGE IN A LARGE COHRT OF PEDIATRIC THALASSEMIA MAJOR PATIENTS Antonella Meloni Received Received
  395-P CMR SURVEY IN A LARGE COHORT OF TI PATIENTS CATEGORIZED IN DIFFERENT TRANSFUSIONAL REGIMENS Antonella Meloni Received Received
  396-P EVALUATION OF GLYCAEMIC ABNORMALITIES IN ?ETA THALASSEMIA MAJOR USING CONTINUOUS GLUCOSE MONITORING SYSTEM AND ORAL GLUCOSE TOLERANCE TEST Mohamed AbdelDaem Mohamed Yassin Received Received
  398-P EFFECTS OF THE ANTI RANK LIGAND DENUSOMAB ON BETA THALASSEMIA MAJOR-INDUCED OSTEOPOROSIS Mohamed AbdelDaem Mohamed Yassin Received Received
  399-P REFERENCE RANGES FOR BIVENTRICULAR VOLUMES AND EJECTION FRACTION AND FOR LEFT VENTRICULAR MASS IN ADULT THALASSEMIA INTERMEDIA PATIENTS WITHOUT MYOCARDIAL IRON OVERLOAD Antonella Meloni Received Received
  400-P CLINICAL EVOLUTION IN FOUR CARRIERS OF BETA GLOBIN LOCUS DELETIONS Felix De la Fuente Received Received
  401-P PITUITARY MRI IN CORRELATION WITH IRON OVERLOAD AND HYPOGONADISM IN YOUNG THALASSEMIA MAJOR PATIENTS Amira Adly Received Received
  402-P HBH CONSTANT SPRING DISEASE (HBHCS) HAS LOWER SERUM FERRITIN RELATIVE TO LIVER IRON CONCENTRATION (LIC) COMPARED TO DELETIONAL HBH DISEASE: IMPORTANCE OF LIC MEASUREMENT IN HBHCS Ai Leen Ang Received Received
  403-P AN AUTOMATIC METHOD FOR MYOCARDIAL T2 CURVE FITTING IN THALASSEMIA PATIENTS WITH SEVERE IRON OVERLOAD Antonella Meloni Received Received
  404-P MOVEMENT ABNORMALITIES IN THE LEFT VENTRICLE OF THALASSEMIA MAJOR PATIENTS Antonella Meloni Received Received
  406-P Mortality sickle cell diseaserisk factors in a Dutch cohort Marein Schimmel Received Received
  407-P PRASUGREL IN CHILDREN WITH SICKLE CELL DISEASE: PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS FROM AN OPEN-LABEL, ADAPTIVE-DESIGN, DOSE-RANGING STUDY Julie Sherman Received Received
  410-P NEWBORN SCREENING FOR SICKLE CELL DISEASE IN BRUSSELS, A PROGRAM WITH AN ONGOING CLINICAL OUTCOME IMPROVEMENT Phu-Quoc L Received Received
  411-P ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE INTRONE4 VNTR POLYMORPHISM IN SICKLE CELL DISEASE AND TRANSFUSION-DEPENDENT ?-THALASSEMIA MAJOR: RELATION TO CARDIO-VASCULAR COMPLICATIONS Azza Tantawy Received Received
  412-P ANTENATAL SCREENING PROGRAMME FOR HAEMOGLOBINOPATHY IN A LOW PREVALENCE AREA: IS IT EFFECTIVE? ANANDIKA LIYANAGE Received Received
  413-P FG4592, A NOVEL INHIBITOR OF THE PROLYL HYDROXYLASE OF HYPOXIA-INDUCIBLE FACTOR (HIF-PH) ELICITED LINEAR-EXPONENTIAL DOSE-RESPONSE PROFILE ON PLASMA ERYTHROPOIETIN (EPO) LEVELS Xia Chen Received Received
  415-P DEVELOPMENT OF A LABORATORY PATHWAY TO ASSIST THE DIAGNOSIS OF HEREDITARY HAEMOCHROMATOSIS IN PRIMARY CARE Catherine Ogilvie Received Received
  418-P INTRAVENOUS IRON THERAPY FOR TREATMENT OF ANEMIA DURING PREGNANCY IS ASSOCIATED WITH IMPROVED MATERNAL QUALITY OF LIFE, LESS POSTNATAL DEPRESSION AND LONGER BREASTFEEDING Alhossain Khalafallah Received Received
  420-P STUDY OF IRON STATUS AS A CONTRIBUTING FACTOR TO ANEMIA IN PEDIATRIC CANCER PATIENTS Azza Tantawy Received Received
  424-P FOUR MEASURES TO REDUCE THE RATE OF HEALTH CARE-ASSOCIATED BLOODSTREAM INFECTIONS RELATED TO THE USE OF NEEDLESS MECHANICAL VALVE CONNECTORS IN LONG-TERM CENTRAL VENOUS CATHETERS Nélson Domingues Received Received
  427-P A RETROSPECTIVE STUDY OF THE RELATIONSHIP BETWEEN VITAMIN D SUPPLEMENTATION AND THE RISK OF FEBRILE NEUTROPENIA(FN) IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES IN EAST KENT HOSPITALS(EKUFHT) Salah-Eldin Alhassan Received Received
  428-P INFECTIONS CAUSED BY CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES Maria Stamouli Received Received
  431-P ABNORMAL SPLEEN FUNCTION ASSESSED BY THE STUDY OF PITS AND SUBMEMBRANOUS VACUOLES IN ERYTHROCYTES IN PATIENTS WITH SPLENOMEGALY OF DIFFERENT ETIOLOGY EVARIST FELIU Received Received
  432-P NEUTROPENIC ENTEROCOLITIS AND VANCOMYCIN RESISTANT ENTEROCOCCUS AS PREDISPOSING FACTOR Elif Gulsum Umit Received Received
  433-P ANAEROBIC BLOODSTREAM INFECTIONS AMONG HAEMATOLOGICAL CANCER PATIENTS: EPIDEMIOLOGY AND OUTCOME. RESULTS OF AN 8-YEAR SURVEILLANCE PROGRAM AT A SINGLE INSTITUTION Chiara Cattaneo Received Received
  434-P COMPARISON OF THE BD GENEOHMVANR ASSAY TO CULTURE FOR IDENTIFICATION OF VANCOMYCIN-RESISTANT ENTEROCOCCI IN RECTAL AND STOOL SPECIMENS IN PEDIATRIC MALIGNANCY PATIENTS yaman yntem Received Received
  435-P REASONS FOR TREATMENT SEEKING DELAY IN NEUTROPENIC SEPSIS Marc Talbot Received Received
  436-P CEFEPIME-INDUCED ENCEPHALOPATHY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: CLINICAL FEATURES AND RISK FACTORS Tomotaka Ugai Received Received
  438-P USEFULNESS OF GALACTOMANNAN ASSAY IN BRONCHOALVEOLAR LAVAGE SAMPLES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES AND RISK OF INVASIVE PULMONARY ASPERGILLOSIS. Rafael Del Orbe Barreto Received Received
  439-P RISK FACTORS RELATED TO MORTALITY IN HEMATOLOGICAL PATIENTS ADMITTED TO INTENSIVE CARE UNIT (ICU) Sandra Iraheta Received Received
  442-P DIAGNOSTIC EFFICACY OF GALACTOMANNAN ASSAY AND COMPUTERIZED CHEST TOMOGRAPHY IN INVASIVE ASPERGILLOSIS OF FEBRILE NEUTROPENIC CHILDREN Gonul Aydogan Received Received
  443-P VESICLES OBSERVED IN LEUCOREDUCED AND NON LEUCOREDUCED CONCENTRATED RED BLOOD CELLS BY MEANS OF ADVANCED MICROSCOPES: POSSIBLE RELATION TO THE STORAGE LESION Dimosthenis Stamopoulos Received Received
  445-P Alloantibody formation is increased in Sickle Cell Disease patients compared to the general population Joep Sins Received Received
  446-P THE ROLE OF BLOOD TRANSFUSION IN BETA-THALASSEMIA: AN EX VIVO STUDY OF HEMOSTATIC PARAMETERS Alice Trinchero Received Received
  448-P TRANSCRIPTIONAL PROFILING OF HUMAN ERYTHROID PROGENITORS FROM G-CSF MOBILIZED AND NONMOBILIZED PERIPHERAL BLOOD Vladan Cokic Received Received
  450-P MATERNAL AND FETAL OUTCOMES IN PREGNANT PATIENTS WITH SICKLE CELL DISEASE WHO APPLIED PROPHYLACTIC RED BLOOD CELL EXCHANGE PROCEDURE Ilknur Kozanoglu Received Received
  452-P ANCESTIM VERSUS PLERIXAFOR FOR THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS Adrian Tempescul Received Received
  453-P BONE MARROW ASPIRATE MORPHOLOGIC, IMMUNOPHENOTYPIC AND CYTOGENETIC EVALUATION IN RELATED DONORS PRIOR TO HEMATOPOIETIC STEM CELL DONATION Raffaella Milani Received Received
  454-P THE USE OF PREOPERATIVE ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WHO UNDERWENT KNEE OR HIP ARTHROPLASTY Ghazi Alotaibi Received Received
  456-P FAILURE ON MAINTAINING HAEMOGLOBIN LEVEL AFTER TRANSFUSION IN TRANSFUSION DEPENDENT THALASSEMIA PATIENTS RELATED TO ERYTHROCYTE ALLOANTIBODY AND AUTOANTIBODY PRODUCTION: PROPORTION AND REL Andree Kurniawan Received Received
  457-P EFFECT OF USING LEUKOSTOP FILTER DURING BLOOD TRANSFUSION ON PULMONARY FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR Iman Ragab Received Received
  458-P PLATELET TRANSFUSIONS IN HAEMATOLOGY PATIENTS bachra choufi Received Received
  459-P THE EFFECTIVENESS OF PLATELETS TRANSFUSIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA (AML) DURING INDUCTION CHEMOTHERAPY (IC). Bulgan Davaasambuu Received Received
  460-P MEASUREMENT OF IRON CONCENTRATION IN HAIR AS AN INDICATOR OF BODY IRON LOAD Yasemin Altuner Torun Received Received
  461-P REVIEW AND DESIGN OF A NEW BLOOD BOOKING PROTOCOL FOR EACH SURGERY AND A RESTROSPECTIVE STUDY OF THE DIRECT EXPENSE DECREASE WITH THE NEW PROTOCOL Angel Pereda Vicandi Received Received
  462-P A CANADIAN TALE OF TWO BLOOD GROUPS Conal McConville Received Received
  466-P RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN COMBINATION WITH LOW-DOSE RITUXIMAB (LD RTX) IN SEVERE OR REFRACTORY PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER PROSPECTIVE CLINICAL TRIAL MING HOU Received Received
  470-P RITUXIMAB VERSUS SPLENECTOMY IN PERSISTENT OR CHRONIC ADULT PRIMARY IMMUNE THROMBOCYTOPENIA: AN ADJUSTED COMPARISON OF MORTALITY AND MORBIDITY Guillaume Moulis Received Received
  471-P EVALUATION OF THE IMMATURE PLATELET FRACTION IN THE DIAGNOSIS AND PROGNOSIS OF CHILDHOOD IDIOPATHIC THROMBOCYTOPENIC PURPURA Amira Adly Received Received
  472-P THALIDOMIDE CORRECTS IMPAIRED MESENCHYMAL STEM CELL FUNCTION IN INDUCING TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA JUN PENG Received Received
  473-P DISEASE PROGRESSION, TREATMENT PATTERNS, AND CO-MORBID BURDEN AMONG ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UPDATED RESULTS FROM THE UNITED KINGDOM ITP REGISTRY Dimitri Bennett Received Received
  474-P THROMBOEMBOLIC EVENTS IN PATIENTS WITH ADULT CHRONIC IMMUNE THROMBOCTOPENIA (ITP) TREATED WITH ELTROMBOPAG shojiro Takagi Received Received
  475-P MANAGEMENT OF ADULT CHRONIC IMMUNE THROMBOCYTOPENIA IN JAPAN: PATIENT AND HEMATOLOGIST PERSPECTIVES Norio Komatsu Received Received
  476-P D-DIMER LEVELS IN ACUTE IDIOPATHIC AND SECONDARY THROMBOTIC THROMBOCYTOPENIC PURPURA Andrew Grosset Received Received
  477-P THROMBOCYTOPENIA IN PREGNANCY: OUR EXPERIENCE AT THE NATIONAL MATERNITY HOSPITAL MATIAS DIAZ Received Received
  478-P MONITORING ANTIPLATELET THERAPY : ACTIVITY OF ADENOSINE DIPHOSPHATE RECEPTOR INHIBITORS IN PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION Marian Fedor Received Received
  479-P ANALYSIS OF RETICULATED PLATELETS IN THE ROUTINE CLINICAL PRACTICE USING THE CELL-DYN SAPPHIRE INSTRUMENT Hans Wadenvik Received Received
  481-P THE ROLE OF OXIDATIVE STRESS IN CHILDREN WITH ACUTE AND CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA Erol Erduran Received Received
  482-P PILOT OBSERVATIONAL STUDY OF ROTATIONAL THROMBOELASTOMETRY (ROTEM) TO PREDICT BLEEDING RISK IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (ATHENA STUDY) Lise Estcourt Received Received
  483-P AUTOCRINE AMPLIFICATION OF INTEGRIN aIIBb3 ACTIVATION AND PLATELET ADHESIVE RESPONSES BY DEOXYRIBOSE-1-PHOSPHATE Dina Vara Received Received
  484-P INCREASED CIRCULATING MICROPARTICLES COEXPRESSING ENDOTHELIAL AND PLATELET MARKERS IN ISCHEMIC CEREBRAL STROKE Ghada Ezzat Received Received
  485-P LOW MOLECULAR WEIGHT HEPARIN (LMWH) FOR PRIMARY THROMBOPROPHYLAXIS OF AMBULATORY PATIENTS WITH SOLID CANCER SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Anat Gafter-Gvili Received Received
  486-P PLATELET COUNTS DECREASE WITH INCREASING LUPUS-LIKE ANTICOAGULANT RATIOS, IRRESPECTIVE OF ANTIPHOSPHOLIPID SYNDROME CRITERIA Marta Pereira Received Received
  487-P REDOX-DEPENDENT ANGIOGENESIS BY NUCLEOSIDE DERIVATIVES OF DEOXYRIBOSE-1-PHOSPHATE Dina Vara Received Received
  488-P THE JAK2 V617F MUTATION IN PATIENTS WITH CEREBRAL VENOUS THROMBOSIS IS ASSOCIATED WITH AN INCREASED RISK OF RECURRENCE Valerio De Stefano Received Received
  490-P ADVANTAGES AND DISADVANTAGES OF INCORPORATING C-REACTIVE PROTEIN LEVELS, AGE AND D-DIMER LEVELS IN DIAGNOSING PULMONARY EMBOLISM Meindert Crop Received Received
  491-P EVALUATING ACQUIRED DISORDERS OF PROTEIN C SYSTEM IN PATIENTS ON VITAMIN K ANTAGONISTS TREATMENT BY THE CALIBRATED AUTOMATED THROMBOGRAM Veronika Shmeleva Received Received
  493-P THE ROLE OF ANTICOAGULANT THERAPIES ON COAGULOPATHY (DISSEMINATED INTRAVASCULAR COAGULATION) IN PATIENTS WITH HEMOLYTICUREMIC SYNDROME AFTER INFECTION WITH ENTEROHEMORRHAGIC ESCHERICHIA COLI O111. Jun Murakami Received Received
  494-P UNEXPECTED FATAL PULMONARY EMBOLISM FOUND AT FORENSIC AUTOPSIES Mariana Villegas Scivetti Received Received
  496-P ANTITHROMBOTIC PROPHYLAXIS IN PREGNANT WOMEN WITH ANTITHROMBIN CONGENITAL DEFICIENCY IS EFFECTIVE IN PREVENTING ADVERSE OUTCOMES Valerio De Stefano Received Received
  497-P HIGH PREVALENCE OF PROTEIN S DEFICIENCY IN THAI POPULATION Ponlapat Rojnuckarin Received Received
  498-P MANAGEMENT OF EXCESSIVE ANTICOAGULATION IN PATIENTS TREATED WITH ACENOCOUMAROL, A VITAMIN K ANTAGONIST. Jesus Cesar Received Received
  499-P GENETIC POLYMORPHISMS RELATED TO HEMOSTASIS AND THEIR ASSOCIATION WITH PRIMARY RECURRENT PREGNANCY LOSS Elvira Guerra-Shinohara Received Received
  500-P HIGH ON-TREATMENT PLATELET REACTIVITY: NOT AN ISOLATED PROBLEM Martin Jakl Received Received
  501-P EVALUATION OF PIVKA-II AS A PREDICTOR MARKER FOR PORTAL VEIN THROMBOSIS IN HEPATOCELLULAR CARCINOMA PATIENTS Maryse Ayoub Received Received
  503-P PERIPHERALLY INSERTED CENTRAL CATHETERS (PICCS) CAN BE SUCCESSFULLY UTILIZED IN HAEMATOLOGICAL PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY OR ALLOGENEIC/AUTOLOGOUS STEM CELL TRANSPLANTATION Alessandra Malato Received Received
  504-P PICC INSERTION AND MANAGEMENT IN HEMATOLOGY PATIENTS: 5 YEARS PROSPECTIVE STUDY THE CAGLIARIS DEPARTMENT OF HAEMATOLOGY Daniele Derudas Received Received
  505-P A NEW SCORE TO DETERMINE THE PROBABILITY OF FINDING AN HLA IDENTICAL UNRELATED DONOR: A VALIDATED EFFICIENT TIME AND COST SAVING METHOD Mauricette Michallet Received Received
  506-P ESTIMATES OF BURDEN OF DISEASE ASSOCIATED WITH MANAGEMENT OF ACUTE MYELOID LEUKEMIA IN UK AND US Izabela Kucmin Received Received
  511-P THE IMPACT OF UNRESTRICTED FUNDING ON HAEMATO-ONCOLOGY TREATMENT CHOICE Tony Todd Received Received
  512-P PATIENT SAFETY AND CLINICAL EFFICIENCY GAINS FOLLOWING IMPLEMENTATION OF AN INTEGRATED HEALTH INFORMATION SYSTEM IN EAST LONDON. Ciara Freeman Received Received
  513-P PHARMACOLOGICAL DRUG EXPENDITURE OF FIRST-LINE INDOLENT NON-HODGKIN LYMPHOMAS IN SPAIN Juan Manuel Collar Received Received
  514-P A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES, UTILITY, RESOURCE USE, AND COST ESTIMATES OF FIRST-LINE TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA Amin Haiderali Received Received
  515-P A COST-BENEFIT ASSESSMENT OF TREATMENT (TX) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: AN EFFICIENCY FRONTIER APPROACH Shien Guo Received Received
  518-P A CALL FOR A STANDARDISED MEASUREMENT OF HAEMOGLOBIN IN THE REPUBLIC OF IRELAND Jennifer O Sullivan Received Received
  519-P DEMAND MANAGEMENT IN A UNIVERSITY LABORATORY IN THE WEST OF IRELAND; THE FINANCIAL BENEFIT OF DISTRIBUTION OF LOCAL GUIDELINES FOR VITAMIN B12 TESTING. Aoibheann Ni Chonfhaola Received Received
  617-P A COHORT STUDY OF POST-RELAPSE/RESISTANCE SURVIVAL IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA TAMARA INTERMESOLI Received Received
  618-P A SEQUENTIAL USE OF TKI, CHEMOTHERAPY AND TRANSPLANT IS ASSOCIATED WITH HIGH COMPLETE REMISSION RATES, DISEASE-FREE AND OVERALL SURVIVAL IN ADULT PH ALL. RESULTS OF THE GIMEMA 0904 PROTOCOL Sabina Chiaretti Received Received
  619-P Comorbidity impacts on complete remission rate in elderly patients with acute lymphoblastic leukemia Colombe Saillard Received Received
  620-P CLL PATIENTS CARRYING 13q DELETION SHOW CLINICAL HETEROGENEITY ACCORDING TO IGHV MUTATIONAL STATUS AND CD38 EXPRESSION Andrea Visentin Received Received
  621-P COMPARABLE OUTCOME OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION AS POST-REMISSION THERAPY IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: INTERIM ANALYSIS OF PROSPECTIVE STUDY Dae-Young Kim Received Received
  623-P MRD LEVEL ANALYSIS IN ADULT ALL PATIENTS. ANALYSIS OF THE CZECH LEUKEMIA STUDY GROUP FOR LIFE (CELL) Cyril álek Received Received
  624-P FLUDARABINE, ARA-C AND LIPOSOMAL DAUNORUBICIN (FLAD) PLUS HEMOPOIETIC STEM CELL TRANSPLANT (HSCT) AS SALVAGE THERAPY IN PATIENTS WITH RELAPSED-REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA. Marino Clavio Received Received
  626-P CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL) : THE BOLOGNA EXPERIENCE mariachiara abbenante Received Received
  627-P ENCOURAGING SURVIVAL IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - RESULTS OF RUSSIAN ACUTE LYMPHOBLASTIC LEUKEMIA (RALL) STUDY GROUP Elena Parovichnikova Received Received
  629-P FOUR YEARS EXPERIENCE WITH HYPER-CVAD TREATMENT OF ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN SWEDEN. POPULATION-BASED DATA. Piotr Kozlowski Received Received
  631-P ADULT MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO THE WHO 2008 CLASSIFICATION A SINGLE CENTER EXPERIENCE Claudia Moreira Received Received
  632-P INTEGRATING ALTERNATIVE DONORS ALLOWS BEST OUTCOMES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIGH RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTRE STUDY Barbara Forno Received Received
  633-P OBESITY, INSULIN RESISTANCE AND ADIPOKINES IN SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. Trkiz Grsel Received Received
  634-P ZAP70 GENE EXPRESSION MAY BE A PROGNOSTIC FACTOR FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS Bing Xu Received Received
  638-P EFFECTS OF PROPHYLACTIC CRANIAL RADIOTHERAPY ON GROWTH HORMONE SECRETION OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA Gonul Aydogan Received Received
  639-P THE IMPACT OF RISK STRATIFICATION BY EARLY BONE-MARROW RESPONSE AND FCM-MRD IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA (A SINGLE INSTITUTION EXPERIENCE IN AZIZA OTHMANA HOSPITAL, TUNIS, TUNISIA). BEN ABDENNEBI Yosr Received Received
  641-P IDENTIFICATION OF NOVEL GENETIC ALTERATIONS BY WHOLE-TRANSCRIPTOME SEQUENCING IN INFANTS WITH CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Marco Togni Received Received
  643-P ALTERED GENES DOWNSTREAM OF MYCN IN ACUTE MYELOID LEUKEMIA IN ZEBRAFISH BY RETINOIC ACID AND VALPROIC ACID Li-Jing SHEN Received Received
  645-P EXPRESSION, REGULATION AND FUNCTIONAL ROLES OF THE CHEMOKINE RECEPTOR CXCR7 IN ACUTE MYELOID LEUKAEMIA CELLS Deog-Yeon Jo Received Received
  646-P INTERLEUKIN-3 RECEPTOR ALPHA CHAIN (CD123) AS A MARKER FOR LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA AND ITS RELATION TO DISEASE PROGRESSION Hanan Alwakeel Received Received
  647-P EFFECTS OF B-MYB ABERRANT EXPRESSION ON HEMATOPOIETIC PROGENITOR CELL GROWTH AND DETECTION OF GENETIC VARIATIONS THAT MAY MODIFY ITS PROTEIN FUNCTION SANDRA DOLZ GIMÉNEZ Received Received
  648-P MUTATIONS IN RUNX1 AND NPM1 COMBINED WITH IMBALANCES OF CHROMOSOME 21 ARE PREDICTIVE FOR PROGRESSION OF AML Katya Gancheva Received Received
  649-P PROGNOSTIC VALUE OF B-MYB AND ITS REGULATION BY MIRNAS IN ACUTE MYELOID LEUKEMIA Marta Llop García Received Received
  651-P CLINICAL AND HEMATOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA WITH REARRANGEMENTS OF EVI1 OR PRDM16 marion eveillard Received Received
  653-P IMPACT OF THE E3 UBIQUITIN LIGASE TRAF2 ON TNF-?-INDUCED APOPTOSIS IN A CELL MODEL OF FLT3-ITD-POSITIVE AML Sebastian Scholl Received Received
  654-P PLUMBAGIN ENHANCED TRAIL-INDUCED APOPTOSIS OF KASUMI-1 CELLS IN NOD / SCID MICE Li-Gen Liu Received Received
  658-P IMPLICATIONS OF MIR-10 IN CHEMOTHERAPY RESPONSE OF NPM1 MUTATED AML ramiro garzon Received Received
  660-P SYNERGISTIC EFFECTS OF HSP70 AND HSP90 INHIBITORS IN PRIMARY HUMAN ACUTE MYELOID LEUKEMIA CELLS Hkon Reikvam Received Received
  662-P IMPROVEMENT, BUT STILL POOR PROGNOSIS FOR ESTONIAN PATIENTS COMPARED TO A WELL-DEFINED REGION OF WESTERN SWEDEN, A POPULATION BASED STUDY OF ACUTE DE NOVO LEUKEMIA PATIENTS AGED 16-64 YEARS Erik Hulegrdh Received Received
  663-P PROGNOSTIC IMPACT OF NPM1, IDH1/2 AND DNAH11 GENE MUTATIONS ON NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA PATIENTS NOT HARBORING FLT3/ITD MUTATION Yeo-Kyeoung Kim Received Received
  664-P ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA Benedetto Bruno Received Received
  667-P SYSTEMIC VERSUS LOCALIZED THERAPEUTIC APPROACH FOR ISOLATED MYELOID SARCOMA: META-ANALYSIS OF INDIVIDUAL PATIENT DATA Darko Antic Received Received
  669-P LOW MDR1 AND BAALC EXPRESSION IDENTIFIES A NEW SUBGROUP OF ADULT CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA WITH A FAVORABLE OUTCOME Xutao Guo Received Received
  670-P THE SURFACE MOLECULAR SIGNATURE OF LEUKEMIC CELLS WAS ASSOCIATED WITH NPM1 AND FLT3-ITD MUTATIONS IN ACUTE MYELOID LEUKEMIA SuJun Gao Received Received
  671-P IMPACT OF DAY 14 BONE MARROW EXAMINATION ON RE-INDUCTION DECISION AND PREDICTION OF COMPLETE RESPONSE IN ACUTE MYELOGENOUS LEUKEMIA (AML) Aamer Aleem Received Received
  672-P ADVERSE PROGNOSTIC SIGNIFICANCE OF FLT3 MUTATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA mirjana mitrovic Received Received
  675-P PERIPHERAL BLOOD BLASTS ON DAY 7 OF INITIAL INDUCTION THERAPY PREDICT RESPONSE TO CHEMOTHERAPY AND SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA SuJun Gao Received Received
  676-P PROGNOSTIC VALUE OF TH17 CELLS IN ACUTE LEUKEMIA Manal Salah Eldin Received Received
  677-P STUDIES ON BCR AND TLR SIGNALLING IN AGGRESSIVE CLL- THE CASE OF STEREOTYPED SUBSET 1 Ann-Charlotte Bergh Received Received
  678-P THE PHOSPHO-PROTEOMIC PROFILE OF CD49D-EXPRESSING CIRCULATING CHRONIC LYMPHOCYTIC LEUKEMIA CELLS IS CONSISTENT WITH CONSTITUTIVE RECEPTORIAL ENGAGEMENT BY BLOOD-BORNE LIGANDS Dania Benedetti Received Received
  682-P SINGLE CELL NETWORK PROFILING (SCNP) ANALYSIS REVEALS DYSFUNCTIONAL SIGNALING WITHIN THE TH17 AXIS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Michelle Atallah Received Received
  684-P EXPRESSION OF ZAP-70 IN CLL ACTIVATES NF-KB SIGNALING Valerie Pede Received Received
  685-P THE PRO-APOPTOTIC MIR-132212/SIRT1/TP53 AXIS IS ACTIVATED UPON B-CELL RECEPTOR TRIGGERING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS Riccardo Bomben Received Received
  686-P HETEROGENEOUS FUNCTIONAL EFFECTS OF CONCOMITANT B CELL RECEPTOR AND TOLL-LIKE RECEPTOR STIMULATION IN CLL WITH MUTATED VERSUS UNMUTATED IMMUNOGLOBULIN GENES Stavroula Ntoufa Received Received
  687-P IGG-SWITCHED CLL HAS A DISTINCT IMMUNOGENETIC SIGNATURE FROM THE COMMON MD VARIANT: ONTOGENETIC IMPLICATIONS Anna Vardi Received Received
  689-P ABERRANT EXPRESSION OF PD-1 IN CHRONIC LYMPHOCYTIC LEUKEMIA IS INDEPENDENT FROM BCR SINGLING AND PDCD1 GENE POLYMORPHISM Maciej Grzywnowicz Received Received
  695-P A NEW ONCOGENIC ROLE OF BCR/ABL-OOF IN CHRONIC MYELOID LEUKAEMIA PATHOGENESIS Cristina Panuzzo Received Received
  697-P MICROVESICLES TRANSCRIPTOME REFLECTS PHYSIOLOGICAL CONDITIONS OF LEUKEMIC PARENTAL CELLS Gloria Milani Received Received
  698-P THE REFERENCE STANDARD FOR BCR-ABL TRANSCRIPT MONITORING IS IMPORTANT TO DEFINE CMR IN CML PATIENTS AND TO TEST THE RQ-PCR METHOD PERFORMANCES Rodica TALMACI Received Received
  700-P IDENTIFICATION AND FOLLOW-UP OF TWO NEW RARE E8A2 BCR-ABL FUSION GENES Sarah Huet Received Received
  702-P EVALUATION OF TOB1 GENE EXPRESSION IN CML PATIENTS AND BLOOD DONOR AND THE EFFECT OF GENE SILENCING IN BCR-ABL CELL LINE CINTIA MASCARENHAS Received Received
  705-P PATTERNS OF ABL KD MUTATION IN ASIAN PATIENTS WITH IMATINIB-RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA Hawk Kim Received Received
  706-P COMPARISON OF NON AUTOMATED BCR-ABL1 RT-QPCR WITH THE XPERT BCR-ABL MONITOR TM ASSAY Stephanie Dulucq Received Received
  711-P LONG-TERM SURVIVAL OUTCOME AND PROGNOSIS IN 2277 PATIENTS WITH CHRONIC MYELOID LEUKAEMIA ALLOCATED TO FIRST-LINE IMATINIB TREATMENT NEW RESULTS FROM THE EUTOS IN-STUDY REGISTRY Markus Pfirrmann Received Received
  713-P DEFINING LOW AND UNDETECTABLE LEVELS OF DISEASE IN CHRONIC MYELOID LEUKAEMIA: PROGRESS TOWARDS STANDARDISATION IN EUROPE Helen White Received Received
  714-P CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES (BCR-ABL1 =10 AT 3 MONTHS AND =1 6 MONTHS) AS A PREDICTOR FOR LONG-TERM OUTCOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB Sung-Eun Lee Received Received
  716-P HEPATITIS B VIRUS REACTIVATION IN CHRONIC MYELOID LEUKEMIA TREATED WITH VARIOUS TYROSINE KINASE INHIBITORS: A MULTICENTER RETROSPECTIVE STUDY Sung-Hyun Kim Received Received
  717-P EARLY AND DEEP RESPONSES TO IMATINIB PREDICT NOT ONLY COMPLETE MOLECULAR RESPONSE BUT ALSO THE PROBABILITY FOR MAINTAINING THE RESPONSE. Valentín García-Gutiérrez Received Received
  720-P IN CML PATIENTS TREATED FRONTLINE WITH IMATINIB, WITH A BCR-ABL RATIO HIGHER THAN 10 AT 3 MONTHS, THE CHANGE TO A 2ND GTKI IS ASSOCIATED WITH IMPROVEMENT OF CYTOGENETIC RESPONSE, BUT NOT WITH MMR LUIS FELIPE CASADO MONTERO Received Received
  721-P CLINICAL AND BIOLOGICAL FEATURES OF BLAST CRISIS (BC) IN PATIENTS WITH PH CHRONIC MYELOID LEUKEMIA (CML) IN THE TKIS ERA: EXPERIENCES IN CLINICAL PRACTICE Antonella Russo Rossi Received Received
  722-P REVERSIBLE LYMPH NODE FOLLICULAR HYPERPLASIA ASSOCIATED WITH DASATINIB TREATMENT FOR CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE Clémence Roux Received Received
  723-P Descriptive study of CML patients in major molecular response (MMR) with an evaluation of clinical and therapeutic characteristics leading to the conversion into a complete molecular response (CMR) Mauricette Michallet Received Received
  726-P EUTOS CML PROGNOSTIC SCORING SYSTEM PREDICTS ELN-BASED EVENT-FREE SURVIVAL BETTER THAN EURO/HASFORD AND SOKAL SYSTEMS IN CHRONIC PHASE CML PATIENTS RECEIVING FRONTLINE IMATINIB MESYLATE Nilgun Sayinalp Received Received
  728-P BONE MARROW IMAGING OF HUMERAL AND FEMORAL MARROW BY MULTI-DETECTOR COMPUTED TOMOGRAPHY IN PATIENTS WITH APLASTIC ANEMIA AND HYPOPLASTIC MDS Tomotaka Ugai Received Received
  730-P BONE MARROW SCREENING FOR MYELODYSPLASIA-RELATED CHANGES AND ABERRANT LYMPHOID POPULATIONS USING ONE TUBE, FOURTEEN ANTIBODY-TEN COLOR FLOW CYTOMETRY PANEL Anna Porwit Received Received
  731-P PLATELET COUNT AND TRANSFUSION-DEPENDENCY AFFECT OVERALL SURVIVAL IN PATIENTS WITH REFRACTORY ANEMIA WITH RING SIDEROBLASTS AND THROMBOCYTOSIS (RARS-T) Gregory Kaufman Received Received
  732-P A PROSPECTIVE PHASE II STUDY OF ATG-CYCLOSPORINE A FOR ADULT SEVERE APLASTIC ANEMIA: MEDIAN 8-YEAR FOLLOW-UP DATA Hawk Kim Received Received
  733-P IMPACT OF THE PROLIFERATION INDEX OF SPECIFIC BONE MARROW CELL COMPARTMENTS FROM MYELODYSPLASTIC SYNDROMES IN THE MONITORIZATION OF THE DISEASE: A PILOT STUDY Sergio Matarraz Received Received
  734-P BENEFITS OF THE USE OF AZACITDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY Claudio Cerchione Received Received
  736-P LONG DURATION OF RESPONSE TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES. MULTICENTER RETROSPECTIVE STUDY OF 36 PATIENTS Carlo Finelli Received Received
  737-P PROLONGED LOW-DOSE AZACITIDINE SCHEDULE IN HIGH-RISK MDS PATIENTS: LONG TERM EFFICACY AND RELATIONSHIP WITH MOLECULAR RESPONSE cristina clissa Received Received
  739-P REAL WORLD USE OF AZACITIDINE IN ELDERLY PATIENTS WITH MDS/AML THE SCOTTISH EXPERIENCE Kirstin Lund Received Received
  740-P MODELLING THE LONG-TERM SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) DEL (5Q) TREATED WITH LENALIDOMIDE Dawn Lee Received Received
  741-P ANALYSIS OF RESPONSE TO ERYTHROPOYESIS STIMULATING AGENTS (ESAS) IN 114 MYELODYSPLASTIC SYNDROME (MDS) PATIENTS FROM REGISTRO CAMPANO DELLE MIELODISPLASIE Claudio Cerchione Received Received
  743-P RISK SCORING SYSTEM USING IPSS-R, LDH AND PERFORMANCE STATUS TO PREDICT THE OUTCOMES OF PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS Sang Kyun Sohn Received Received
  744-P PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE: DIAGNOSTIC AND CLASSIFICATION OF 103 BRAZILIAN PATIENTS ANA PAULA AZAMBUJA Received Received
  745-P ERYTHROPOIETIC ASPECTS IN MDS PATIENTS RESPONDERS TO ESAS TREATMENT Claudio Cerchione Received Received
  746-P COMPARISON OF IPSS AND R-IPSS IN A SINGLE UNIT PATIENT COHORT Francesca Pierdomenico Received Received
  747-P DOES REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-R) HAVE ANY IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS? Zhenwei Teo Received Received
  749-P NEW STRATEGIES OF ANALYSIS WITH FLOW CYTOMETRY FOR THE DIAGNOSIS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA Paola Beneit Received Received
  750-P FREQUENT MUTATION OF THE MYD88 GENE IN MACROGLOBULINEMIA Naoki Mori Received Received
  751-P THE ROLE OF FLT3-LIGAND IN THE PROGRESSION OF MULTIPLE MYELOMA; FLT3-LIGAND RELEASED FROM BONE MARROW STROMAL CELLS ACTIVATED PI3K/AKT PATHWAY AND WNT SIGNALING Sung-Soo Yoon Received Received
  752-P CIRCULATING MICRORNA AS POTENTIAL BIOMARKERS OF MGUS AND MM Lenka Kubiczkova Received Received
  754-P DEF124B, A MEMBER OF THE ?-DEFENSINS, IS DOWNREGULATED IN DIFFERENTIATING OSTEOBLASTS BY EXPOSURE TO IMIDS AND MAY MEDIATE THE SUPPRESSIVE EFFECT OF THESE AGENTS ON OSTEOGENESIS Heinz Ludwig Received Received
  755-P IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 IN MYELOMA Jacqueline Noll Received Received
  757-P NEUTROPHILS ARE IMPAIRED IN MULTIPLE MYELOMA BUT NOT IN MGUS ALESSANDRA ROMANO Received Received
  758-P IDENTIFICATION OF INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7 (IGFBP7) AS TUMOR SUPPRESSOR IN MULTIPLE MYELOMA LINKED TO THE PRESENCE OF OSTEOLYTIC LESIONS AND OVERALL SURVIVAL Heinz Ludwig Received Received
  759-P HIGH RISK CYTOGENETIC ABNORMALITIES AND PLASMA CELLS PHENOTYPE INDUCE SIGNIFICANT ALTERATIONS IN BONE MARROW B-CELL COMPARTMENTS IN MONOCLONAL GAMMOPATHIES Sofia Ramos Received Received
  760-P ANGIOPOIETIN-2 AND MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA HAVE DUAL EFFECT ON BONE INVOLVEMENT AND ANGIOGENESIS IN MULTIPLE MYELOMA George Tsirakis Received Received
  761-P GENE EXPRESSION OF BONE MODULATORS IN WHOLE BONE MARROW BIOPSIES IN CORRELATION TO DYNAMIC BONE MARKERS IN MULTIPLE MYELOMA BONE DISEASE Ida Bruun Kristensen Received Received
  762-P P15 AND DAPK METHYLATION IN MULTIPLE MYELOMA AND MGUS: COMPARISON BETWEEN BONE MARROW AND PERIPHERAL BLOOD Catarina Geraldes Received Received
  768-P SAFETY AND EFFICACY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS ENROLLED IN THE MM-002 PHASE 2 TRIAL Paul Richardson Received Received
  769-P CONSOLIDATION WITH HD- MELPHALAN AND AUTOTRANSPLANT (ASCT) AFTER SECOND-LINE TREATMENT INCREASES RESPONSE RATE AND PROGRESSION-FREE SURVIVAL IN MYELOMA PATIENTS RELAPSED AFTER FIRST-LINE ASCT Claudia Crippa Received Received
  770-P TOTAL THERAPY 3 (TT3)-BASED TREATMENT FOR MULTIPLE MYELOMA AN EXTENDED SINGLE CENTER EXPERIENCE Eli muchtar Received Received
  772-P MM-008: A PHASE 1 TRIAL EVALUATING PHARMACOKINETICS AND TOLERABILITY OF POMALIDOMIDE LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH RENAL IMPAIRMENT Jeffrey Matous Received Received
  773-P CAUSES OF DEATH 30 AND 180 DAYS AFTER DIAGNOSIS IN NON-HDT TREATED DANISH MULTIPLE MYELOMA PATIENTS: A STUDY FROM THE DANISH MYELOMA STUDY GROUP Morten Orebo Holmstrm Received Received
  774-P PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) Elizabeth Bilotti Received Received
  777-P THE UK LENALIDOMIDE TREATMENT CONTINUATION SCHEME: TRENDS OF LONG-TERM TREATMENT IN A CLINICAL SETTING Cathy Williams Received Received
  778-P THE EFFICACY AND SAFETY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IS NOT IMPACTED BY AGE IN PATIENTS WITH ADVANCED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: MM-002 SUBGROUP ANALYSIS Sundar Jagannath Received Received
  779-P PROMISING ROLES OF AMIFOSTINE AS PROPHYLACTIC AGENTS AGAINST BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY Meiyun Fang Received Received
  780-P MP VS MPT IN FIRST TO FOURTH LINE OF TREATMENT IN MULTIPLE MYELOMA PATIENTS Johan Lund Received Received
  781-P CAN NOVEL AGENTS OVERCOME THE NEGATIVE PROGNOSTIC IMPACT OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA? - A POPULATION BASED STUDY INCLUDING 1538 PATIENTS Katarina Uttervall Received Received
  784-P SESTAMIBI TECHNETIUM-99M BONE MARROW SCAN IS ABLE TO PREDICT OVERALL DISEASE OUTCOME AND MORTALITY COMPARED TO WHOLE BODY MAGNETIC RESONANCE IMAGING IN MULTIPLE MYELOMA Alhossain Khalafallah Received Received
  788-P ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE LOW-DOSE DEXAMETHASONE (POM LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Michel Delforge Received Received
  789-P VTD CONSOLIDATION, WITHOUT BISPHOSPHONATES, REDUCES BONE RESORPTION AND IS ASSOCIATED WITH A VERY LOW INCIDENCE OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA POST-ASCT Dimitrios Christoulas Received Received
  790-P IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) INDUCTION FOLLOWED BY LEN MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: MM-015 POST-HOC ANALYSIS Michele Cavo Received Received
  791-P TREATMENT WITH BORTEZOMIB-BASED REGIMENS IMPROVES OVERALL RESPONSE AND PREDICTS FOR SURVIVAL IN PATIENTS WITH PRIMARY OR SECONDARY PLASMA CELL LEUKEMIA: ANALYSIS OF THE GREEK MYELOMA STUDY GROUP Eirini Katodritou Received Received
  792-P EUROPEAN POST-APPROVAL SAFETY STUDY (PASS) OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED DATA ON SAFETY AND SPM INCIDENCE IN PATIENTS TREATED WITH LENALIDOMIDE, THALIDOMIDE, AND BORTEZOMIB Michele Cavo Received Received
  794-P CIRCULATING SOLUBLE RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B LIGAND (SRANKL) AND C-C MOTIF LIGAND-3 (CCL-3) LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH WALDENSTROMS MACROGLOBULINEMIA Dimitrios Christoulas Received Received
  795-P RESULTS OF THE DUTCH COMMUNITY BASED TRIAL VALEO WITH BORTEZOMIB TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS Richard Milek Received Received
  797-P HIGH RISK CYTOGENETICS, ELEVATED LDH AND ISS-3 IDENTIFY A SUBGROUP OF MYELOMA PATIENTS WITH VERY POOR PROGNOSIS Efstathios Kastritis Received Received
  798-P BONE BIOMARKERS ARE USEFUL IN MONITORING MYELOMA BONE DISEASE AND AS EARLY PREDICTOR FOR RELAPSE DISEASE IN MULTIPLE MYELOMA Kay Reen Ting Received Received
  799-P EX VIVO PHARMACOLOGICAL EVALUATION OF 19 DRUGS IN AN AVERAGE OF 50 MULTIPLE MYELOMA PATIENTS USING WHOLE BONE MARROW SAMPLES ANALYZED BY AUTOMATED FLOW CYTOMETRY Belén Liébana Received Received
  800-P THE IMPACT OF 8 GY ONE FRACTION RADIOTHERAPY ON PAIN RELIEF AND RECALCIFICATION IN MULTIPLE MYELOMA PATIENTS WITH PAINFUL BONE DESTRUCTIONS. Milda Rudzianskiene Received Received
  801-P RESULTS OF LENALIDOMIDE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN A REAL WORLD SETTING: FEASIBILITY AND FACTORS CONTRIBUTING TO LONG TREATMENT DURATION Gunter Derigs Received Received
  802-P THE PRESENCE OF IMMUNOPHENOTYPIC ALTERATIONS IN BONE MARROW CELLS OTHER THAN PLASMA CELLS FROM MULTIPLE MYELOMA PATIENTS PREDICTS FOR MYELODYSPLASIA-ASSOCIATED CYTOGENETIC ABNORMALITIES Sergio Matarraz Received Received
  804-P FLOW CYTOMETRIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: A COMPARISON BETWEEN FLOW CYTOMETRIC IMMUNOPHENOTYPING AND CYCLOSCOPE-MG. GIACOMA DE TULLIO Received Received
  805-P NUMBER OF ADVERSE CYTOGENETIC LESIONS DETECTED BY FISH IS ASSOCIATED WITH PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-BASED REGIMENS Norbert Grzasko Received Received
  806-P EVALUATION OF TNF SUPERFAMILY MOLECULES IN MULTIPLE MYELOMA PATIENTS: CORRELATION WITH BIOLOGICAL AND CLINICAL FEATURES. Bolkun Lukasz Received Received
  807-P TOXICITY PROFILE DURING TREATMENT WITH BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Heinz Ludwig Received Received
  808-P VALUE OF WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IN THE STUDY OF MONOCLONAL GAMMOPATHIES AND CORRELATION WITH BONE-RELATED CYTOKINES RAFAEL MARTOS MARTINEZ Received Received
  809-P THE COMBINATION OF BORTEZOMIB AND DEXAMETHASONE (VD) ALONG WITH ZOLEDRONIC ACID INCREASES BONE MINERAL DENSITY (BMD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A PHASE II STUDY Dimitrios Christoulas Received Received
  810-P LONG TERM THERAPY WITH LENALIDOMIDE DOES NOT SIGNIFICANTLY AFFECT THE CELLULAR COMPOSITION OF THE BONE MARROW Annamaria Brioli Received Received
  811-P A RETROSPECTIVE REVIEW OF THE INCIDENCE OF CONTRAST INDUCED NEPHROPATHY IN THE MYELOMA SETTING Maeve Crowley Received Received
  812-P EFFECTS OF BORTEZOMIB ON RENAL IMPAIRMENT MULTIPLE MYELOMA PATIENTS wenming chen Received Received
  813-P THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS Jian Hou Received Received
  816-P LONG TERM FOLLOW-UP OF TREATMENT WITH IMATINIB IN EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS WITH PDGFR REARRANGEMENTS IN ADVANCED PHASE Georgia Metzgeroth Received Received
  819-P HOW MANY CHILDREN WITH THROMBOCYTOSIS OF UNDEFINED ORIGIN HAVE A MYELOPROLIFERATIVE NEOPLASM? Maria Luigia Randi Received Received
  821-P CLINICAL FEATURES OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPLICATED BY PORTAL HYPERTENSION Matthew Yan Received Received
  822-P EOSINOPHILIA IN ROUTINE BLOOD SAMPLES AND THE SUBSEQUENT RISK OF HEMATOLOGICAL MALIGNANCIES AND DEATH Christen Andersen Received Received
  823-P CHRONIC MYELOPROLIFERATIVE NEOPLASMS REVEAL INCREASED RISK OF OSTEOPOROTIC FRACTURES Sarah Farmer Received Received
  824-P DETERMINANTS AND FREQUENCY OF THROMBOTIC AND BLEEDING COMPLICATIONS IN AN ITALIAN COHORT OF 88 PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN): THE ROLE OF ADAMTS-13 AND VWF ACTIVITIES Augusto B Federici Received Received
  825-P INTERNATIONAL PROGNOSTIC SCORE FOR ESSENTIAL THROMBOCYTHEMIA (IPSET) AND IPSET-THROMBOSIS ONE CENTRE ANALYSIS TERESA GARRIDO Received Received
  826-P BCR/ABL EXPRESSION IN CHRONIC MYELOPROLIFERATIVE DISORDERS Laura Kesaeva Received Received
  827-P A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF) Jessica Litvan Received Received
  829-P ADDITION OF THE DEGREE OF BONE MARROW FIBROSIS TO IPSS IN NEW SCORING SYSTEM IMPROVES PREDICTION OF SURVIVAL IN PRIMARY MYELOFIBROSIS Danijela Lekovic Received Received
  830-P CONTRIBUTION OF SNP ARRAYS TO THE DIAGNOSIS AND PROGNOSIS OF CMML. A STUDY OF PATIENTS WITH LOW RISK CYTOGENETIC FEATURES AND CASES WITH ABSENCE OF METAPHASES Laura Palomo Received Received
  832-P HIGHLY SPECIFIC QPCR ASSAYS USING CONSENSUS LNA PROBE FOR THE DETECTION OF t(11;14) AND t(14;18) IN NON-HODGKIN LYMPHOMA WITH A SENSITIVITY OF 10-5 FOR QUANTIFICATION OF MINIMAL RESIDUAL DISEASE Camilla Darum Srensen Received Received
  834-P NR4A1 MEDIATED APOPTOSIS SUPPRESSES LYMPHOMAGENESIS IN A XENOGRAFT MOUSE MODEL Alexander Deutsch Received Received
  835-P EZH2 EXPRESSION DETERMINED BY IMMUNOHISTOCHEMISTRY DOES NOT CORRELATE WITH THE PRESENCE OF EZH2 MUTATIONS IN A SERIES OF DIFFUSE LARGE B-CELL LYMPHOMAS (DLBCL) Mar Garcia Received Received
  836-P DLBCL BIOLUMINESCENT XENOGRAFT MODEL FOR NON-INVASIVE FOLLOW-UP OF ANTITUMOR EFFECT María José Moreno Jiménez Received Received
  837-P BLOOD AND LYMPHATIC MICROENVIRONMENT, MACROPHAGE COMPONENT AS PROGNOSTIC MARKERS IN FOLLICULAR LYMPHOMA Ekaterina Nesterova Received Received
  841-P IDENTIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) SUBTYPES DEFINED BY THE EXPRESSION OF STROMAL PROTEINS AND THEIR ASSOCIATION WITH MICRORNAS INVOLVED IN ANGIOGENESIS Natália Borges Received Received
  842-P DISTINCT GENE EXPRESSION PROFILES IN A CANINE MODEL OF HUMAN DLBCL Geertruy te Kronnie Received Received
  844-P CLINICAL SYMPTOM OR SIGN-DIRECTED SURVEILLANCE CAN BE MORE USEFUL TO DETECT RELAPSE COMPARED TO ROUTINE IMAGING IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AFTER COMPLETE REMISSION Junshik Hong Received Received
  845-P VIROLOGICAL SUCCESS IS ASSOCIATED WITH FAVORABLE PROGNOSIS IN PATIENTS WITH HEPATITIS C ASSOCIATED B-CELL NON-HODGKIN LYMPHOMAS, NATIONAL ANRS HC-13 LYMPHO-C STUDY RESULTS. Jean Marie Michot Received Received
  847-P HIGH-DOSE METHOTREXATE, HIGH-DOSE CYTARABINE AND TEMOZOLOMIDE FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA maher salamoon Received Received
  850-P LENALIDOMIDE PLUS RITUXIMAB-CHOP21 IN ELDERLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA IS PROMISING: LONG TERM RESULTS OF THE PHASE II REAL07 STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL) Annalisa Chiappella Received Received
  851-P PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL) Pam Milner Received Received
  852-P PROSPECTIVE COHORT STUDY FOR SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH RITUXIMAB-CHOP Seok Jin Kim Received Received
  853-P INTERIM PET-CT SCAN AFTER 2 CYCLES SUCCESSFULLY PREDICTS OUTCOME IN DLBL BUT INTRODUCES SIGNIFICANT SELECTION BIAS. Nicholas Grigoropoulos Received Received
  854-P STAGING NEWLY DIAGNOSED LYMPHOMAS: COMPARISON BETWEEN WHOLE BODY-MRI/DWIBS AND 18FDG-PET/CT Carla Minoia Received Received
  855-P CENTRAL NERVOUS SYSTEM RELAPSE IN NON HODGKIN LYMPHOMA: PROGNOSTIC FACTORS AND OUTCOME IN A COHORT OF 304 PATIENTS Juanjosé Alonso Received Received
  856-P LYMPHOCYTE COUNT AT DIAGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA IN THE ERA OF IMMUNOCHEMOTHERAPY WITH RITUXIMAB: IS 1000/MM3 STILL THE BEST CUT-OFF VALUE TO USE TO DEFINE LYMPHOPENIA ? Alessia Bari Received Received
  859-P PROGNOSTIC FACTORS IN VERY OLD PATIENTS (= 75 YEARS) WITH FOLLICULAR LYMPHOMA: A MULTICENTRE RETROSPECTIVE STUDY Anne Parcelier Received Received
  860-P EFFICACY AND SAFETY OF LENALIDOMIDE WITH/WITHOUT RITUXIMAB OR STEROIDS IN HEAVILY PRETREATED NON-HODGKINS B-CELL LYMPHOMAS: RESULTS OF A RETROSPECTIVE STUDY ANNALISA CHIAPPELLA Received Received
  862-P SERUM FREE LIGHT CHAINS LEVELS IN PATIENTS WITH HIV-RELATED LYMPHOMA ARE LOWER AT COMPLETE RESPONSE THAN AT DIAGNOSIS Maria Joao Baptista Received Received
  863-P PROGNOSTIC RELEVANCE OF FDG-PET IN PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA Gayane Tumyan Received Received
  864-P FC-GAMMA-RECEPTOR IIIA POLYMORPHISM AND GENE EXPRESSION PROFILE DO NOT INFLUENCE TREATMENT OUTCOMES AND SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP PROTOCOL Laszlo Varoczy Received Received
  865-P INTENSIFIED PROGRAM INCLUDING BENDAMUSTINE, HIGH DOSE THERAPY AND AUTOGRAFT FOR PATIENTS WITH RELAPSED OR RESISTANT FOLLICULAR NON HODGKIN LYMPHOMA: RESULTS FROM AN EXPLORATORY GITIL STUDY Caterina Patti Received Received
  866-P THE INTENSITY AND DURATION OF PAIN ASSOCIATED WITH TREPHINE BIOPSY Waleed Ghanima Received Received
  869-P THE ROLEOF PET/CT FOR EVOLUATION OF THE BONE MARROW INVOLVEMENT IN LYMPHOMA PATIENTS asu fergun yilmaz Received Received
  870-P ANALYSIS OF THE BONE MARROW INFILTRATION IN A GROUP OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA BY COMPARING BONE MARROW BIOPSY AND 18F-FDG PET/CT Paula César Received Received
  871-P COMPARISONS OF B-CELL AND T-CELL LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS Jui-Ting Yu Received Received
  873-P HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE ADULT LYMPHOMA WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION Eisei Kondo Received Received
  874-P A MULTICENTRE REVIEW OF THE OUTCOMES OF PATIENTS ABOVE THE AGE OF 75 WITH PRIMARY DIFFUSE LARGE B CELL LYMPHOMA Vikramajit Singh Received Received
  875-P HUMAN CORD BLOOD CD45 CELLS PROTECT MICE BRAIN AFTER CLOSED HEAD INJURY Hadar Arien-Zakay Received Received
  876-P PYROSEQUENCING IS A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY Federica Cattina Received Received
  878-P DIFFERENT DOSE OF ATG INDUCTION THERAPY IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: LONG TERM EFFECT ON TH17 AND CONVENTIONAL T CELLS, NOT ON NK RESPONSES Xiang-Yu Zhao Received Received
  879-P CIRCULATING ENDOTHELIAL CELLS (CEC) ARE A RELIABLE AND DYNAMIC BIOMARKER OF ACUTE GVHD (AGVHD) IN PATIENTS UNDERGOING ALLOGENEIC STEM CELLS TRANSPLANTATION. Andrea Di Palma Received Received
  880-P EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION ON THE EXPRESSION OF REGULATORY GAMMA DELTA T CELLS Qifa Liu Received Received
  883-P PARALEL STUDY OF CHIMERISM AFTER ALLOGENIC HAEMTOPOIETIC STEM CELL TRANSPLANTATION MONITORED BY TWO DIFFERENT MOLECULAR METHODS Eva Hanusovska Received Received
  884-P VENO-OCCLUSIVE DISEASE MAY DEVELOP IN SECONDARY IRON OVERLOADED MICE AFTER TOTAL BODY IRRADIATION. Dae Chul Jeong Received Received
  887-P STUDY OF SOLUBLE HLA-G LEVEL DYNAMICS IN HEMATOLOGICAL PATIENTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION Elena Ribakovsky Received Received
  889-P CONTROLLED EPSTEIN-BARR VIRUS REACTIVATION AFTER ALLOGENIC TRANSPLANTATION IS ASSOCIATED WITH IMPROVED SURVIVAL ASSOCIATED TO AN EXPANSION OF NATURAL KILLER CELLS (NK). JEAN FRANCOIS ROSSI Received Received
  890-P MYELOABLATIVE FLUDARABINE PLUS BUSULFAN IV (FB4) REGIMEN COMPARES FAVOURABLY WITH CYCLOPHOSPHAMIDE PLUS BUSULFAN (BUCY) IN PATIENTS UNDERGOING ALLO-SCT FOR MYELOID MALIGNANCY Valerie COITEUX Received Received
  891-P LONG-TERM OUTCOME (BEYOND 10 YEARS) AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION WITH REDUCED-INTENSITY COMPARED TO MYELOABLATIVE CONDITIONING; SIMILAR SURVIVAL BUT DIFFERENT PATTERN OF LATE EVENTS Avichai Shimoni Received Received
  892-P HOW MANY AML PATIENTS DO RECEIVE EARLY ALLOGENEIC BONE MARROW TRANSPLANT AND WHICH TRANSPLANT IS PERFORMED? REAL LIFE DATA FROM GENOVA ACUTE LEUKEMIA REGISTRY (REGAL). Marino Clavio Received Received
  893-P THE MANAGEMENTS OF EBV-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Qifa Liu Received Received
  894-P ASSOCIATION OF HLA POLYMORPHISMS WITH EPSTEIN-BARR VIRUS INFECTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION Qifa Liu Received Received
  895-P PERFORMANCE OF FECAL CALPROTECTIN FOR THE DIAGNOSIS AND FOLLOW UP OF ACUTE GASTRO-INTESTINAL GRAFT VERSUS HOST DISEASE Marta Lisa Battista Received Received
  896-P IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA Luisa Giaccone Received Received
  898-P THREE DAYS BUSULFAN ASSOCIATED WITH FLUDARABINE AND ANTITHYMOGLOBULINE CONDITIONING: IS IT SAFE? Sylvain Chantepie Received Received
  899-P IMPROVED OUTCOME WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A POOR PROGNOSTIC SUBGROUP OF PATIENTS WITH MIXED-LINEAGE-LEUKEMIAREARRANGED LEUKEMIA: RESULTS FROM A SINGLE-CENTER PROSPECTIVE STUDY yu wang wang Received Received
  902-P MOBILIZATION AND ENGRAFTMENT OF PERIPHERAL BLOOD STEM CELLS IN RELATED HEALTHY DONORS OLDER THAN 55 YEARS Cristina Motlló Received Received
  903-P EFFICACY OF ORAL BUDESONIDE FOR GASTROINTESTINAL GRAFT VERSUS HOST DISEASE IN HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS Mui Fong Chong Received Received
  905-P MYELOABLATIVE CONDITIONING REGIMEN WITHOUT ATG AND TBI IN SINGLE UNIT UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH HEMATOLOGIC MALIGNANCIES Juan Tong Received Received
  907-P IMPACT OF INAPPROPRIATE MICAFUNGIN PROPHYLAXIS IN A BONE MARROW TRANSPLANTATION (BMT) UNIT ON THE OUTCOME OF CANDIDIASIS AND ON THE EMERGENCE OF ECHINOCANDIN-RESISTANT CANDIDA KRUSEI ISOLATES Emmanuelle Tavernier Received Received
  909-P SIMILAR OUTCOMES BETWEEN YOUNGER AND OLDER AGE GROUP IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA WHO RECEIVED HLA-MATCHED SIBLING TRANSPLANTS WITH FLUDARABINE-BASED CONDITIONING Seung Hwan Shin Received Received
  910-P POORER OUTCOME AFTER CORD BLOOD THAN AFTER MATCHED RELATED OR UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION PREPARED WITH REDUCED TOXICITY CONDITIONING FOR HIGH RISK ACUTE MYELOID LEUKEMIA devillier raynier Received Received
  912-P KIR-LIGAND INCOMPATIBILITY IN THE GRAFT-VERSUS-HOST DIRECTION DID NOT AFFECT OUTCOMES OF SINGLE UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT ATG FOR ACUTE LEUKEMIA IN COMPLETE REMISSION Junji Tanaka Received Received
  914-P PROGNOSTIC IMPACT OF CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS WITH MYELOID NEOPLASMS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION A SINGLE INSTITUTION SERIES Desire Gijima Received Received
  915-P IN VIVO T-CELL DEPLETION WITH LOW-DOSE ANTITHYMOCYTE GLOBULIN TO REDUCE ACUTE GVHD IN UNRELATED DONOR STEM CELL TRANSPLANT FOR PATIENTS WITH SEVERE APLASTIC ANEMIA Sung-Eun Lee Received Received
  916-P IMPACT OF ABO INCOMPATIBILITY ON UNRELATED CORD BLOOD TRANSPLANTATION Yao Wen Received Received
  917-P SECONDARY ANTIFUNGAL PROPHYLAXIS BASED ON RESPONSE TO INITIAL ANTIFUNGAL THERAPY FOR PATIENTS WITH A HISTORY OF INVASIVE PULMONARY ASPERGILLOSIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION Qifa Liu Received Received
  918-P A MONOCLONAL PROTEIN FOUND IN RELATED STEM CELL DONORS: ARE WE DOING IT RIGHT? Nicolette Tiren-Verbeet Received Received
  919-P TBI AND CYCLOPHOSPHAMIDE PLUS ATG IS WELL TOLERATED AND EFFECTIVE AS A PREPARATIVE REGIMEN FOR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION Haixia Fu Received Received
  920-P HIGH LEVEL OF VASCULAR ENDOTHELIAL GROWTH FACTOR IS ASSOCIATED WITH INCREASED RELAPSE RATE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Ivan Moiseev Received Received
  921-P CLINICAL IMPACT OF ENGRAFTMENT SYNDROME IN ADULT PATIENTS WHO RECEIVED ALLOGENEIC STEM CELL TRANSPLANTATION Hiroaki Shimizu Received Received
  924-P THERAPEUTIC APPROACH TO RELAPSE OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Claudia Moreira Received Received
  925-P IMPACT OF THE 2009 UK UMBILICAL CORD BLOOD TRANSPLANT CONSENSUS STATEMENT ON PRACTICE AND OUTCOMES AT A SINGLE TRANSPLANT CENTRE chloe anthias Received Received
  926-P CMV-SPECIFIC CD8 T-CELL IMMUNE RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION MONITORED BY HLA-MULTIMERS EDUARDO OLAVARRIA Received Received
  927-P IDENTIFICATION OF THE EARLIEST BRANCH POINT FOR MYELO-ERYTHROID DEVELOPMENT IN ADULT HEMATOPOIESIS Kohta Miyawaki Received Received
  932-P Studies of JARID1B in Hematopoiesis Using Gene Knockdown and Overexpression Assay Jingxuan Zhang Received Received
  933-P ROLE OF BMI-1 IN NORMAL MOUSE HEMATOPOIETIC STEM CELLS AND LEUKEMIC CELLS Yuk Man Lam Received Received
  934-P CONNECTIVE TISSUE GROWTH FACTOR (CTGF) CONFERS CELL ADHESION-MEDIATED DRUG-RESISTANCE (CAM-DR) IN ACUTE MYELOID LEUKEMIA Saskia Pante Received Received
  935-P HUMAN BONE MARROW ADIPOCYTES MAINTAIN THE SURVIVAL AND DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS Giulia Maurizi Received Received
  937-P ANALYSIS OF HUMAN ENDOSTEAL HSC NICHE; A NOVEL POPULATION WITH HIGH EXPRESSION OF CD34 AND ESAM IS ADJACENT TO TRABECULAR AREAS OF HUMAN BONE MARROW MICHIKO ICHII Received Received
  938-P HEAD-TO-HEAD COMPARATIVE STUDY OF WHARTONS JELLY AND BONE MARROW MESENCHYMAL STEM CELLS Charalampos Pontikoglou Received Received
  939-P ALTERATION IN GENE EXPRESSION PATTERN IN STROMAL PRECURSOR CELLS OF PATIENTS BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION Irina Shipounova Received Received
  940-P ROLE OF BONE MARROW STROMAL CELLS IN THE REGULATION OF HUMAN EARLY LYMPHOPOIESIS Kohshi Ohishi Received Received
  941-P DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA Francesco Dalò Received Received
  943-P UMBILICAL CORD MESENCHYMAL STEM CELLS WITH IMPROVED SUPPORT FOR HEMATOPOIETIC STEM CELL EXPANSION. Pavel Butylin Received Received
  944-P ENDOTHELIAL CELLS EXPRESSING CONSTITUTIVELY ACTIVE AKT1 ARE CAPABLE OF RECONSTITUTING OF VASCULAR NICHE IN VITRO. Pavel Butylin Received Received
  945-P CHEMOKINE SIGNALLING REGULATES HAEMOPOIETIC STEM CELL PROPERTIES Amy Sinclair Received Received
  947-P MONOALLILIC MUTATIONS OF FHL-RELATED GENES PREDISPOSE TO MACROPHAGE ACTIVATION SYNDROME Elena Sieni Received Received
  949-P COMBINED APPLICATION OF MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION AND FLUORESCENCE IN SITU HYBRIDIZATION TO DETECT CYTOGENETIC ABNORMALITIES IN MULTIPLE MYELOMA Donat Alpar Received Received
  950-P COMPARISON OF MICROARRAY-BASED GENOMIC PROFILING AND MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) FOR THE DETECTION OF CLINICALLY RELEVANT GENETIC LESIONS, INCLUDING IKZF1, IN ALL Marian Stevens-Kroef Received Received
  955-P ARRAY-BASED GENOMIC PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IDENTIFIES HIGHER NUMBER OF PROGNOSTIC RELEVANT GENOMIC ALTERATIONS AND REVEALS NEW RECURRENT GENOMIC ABNORMALITIES Marian Stevens-Kroef Received Received
  956-P DEREGULATION OF STEM CELL FACTOR (SCF)-AKT-S6 PATHWAY IN DIAGNOSTIC AML SAMPLES IS ASSOCIATED WITH DISEASE-FREE SURVIVAL: RESULTS OF A VERIFICATION STUDY Michelle Atallah Received Received
  957-P HIGH-RESOLUTION GENOMIC PROFILING IN MULTIPLE MYELOMA IDENTIFIES RECURRENT PROGNOSTIC RELEVANT COPY NUMBER ALTERATIONS AND REVEALS NEW RECURRENT GENOMIC ABNORMALITIES Marian Stevens-Kroef Received Received
  959-P IMPORTANCE OF MICROARRAY ANALYSIS AS A PROGNOSTIC CLINICAL TOOL IN CHRONIC LYMPHOCYTIC LEUKEMIA Nolwen Prie Received Received
  961-P CHARACTERISTICS OF VARIANT AND ADDITIONAL CYTOGENETIC ABNORMALITIES IN ACUTE MYELOID LEUKEMIA WITH RECURRENT GENETIC ABNORMALITIES Eunhae Cho Received Received
  962-P MUTATIONAL STUDY OF DNMT3A IN ACUTE MYELOID LEUKEMIA Seung Hwan Oh Received Received
  965-P EX VIVO SENSITIVITY AND RESISTANCE MECHANISMS TO CLOFARABINE IN CHILDHOOD ACUTE LEUKEMIA Baleydier Frederic Received Received
  967-P TRANSCRIPT LEVELS AND COPY NUMBER VARIATION OF THE ABCC3 EFFLUX TRANSPORTER CAN PREDICT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA PATIENTS Athina Giannoudis Received Received
  968-P TARGETING THE DBC1-SIRT1-P53 AXIS IS A PROMISING THERAPEUTIC STRATEGY IN FLT3-ITD-POSITIVE AML Daniel Sasca Received Received
  969-P TRANSCRIPTIONAL PROGRAMMES ASSOCIATED WITH EVI1 MEDIATED CHEMOTHERAPY RESISTANCE OF HUMAN MYELOID CELLS Rotraud Wieser Received Received
  970-P KNOCKDOWN OF NUCLEOPHOSMIN BY RNA INTERFERENCE REVERSES MULTIDRUG RESISTANCE IN RESISTANT LEUKEMIC HL-60 CELLS Jianda Hu Received Received
  972-P POLYMORPHISMS OF MULTIDRUG RESISTANCE TRANSPORTER (ABCG2 AND ABCB1) GENES IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA Hajnalka Andrikovics Received Received
  976-P EVIDENCE THAT THE PREGNANE X AND RETINOID RECEPTORS PXR, RAR AND RXR MAY REGULATE TRANSCRIPTION OF THE IMATINIB TRANSPORTER HOCT1 EXPRESSION IN CHRONIC MYELOID LEUKAEMIA CELLS Lihui Wang Received Received
  977-P THE ROLE OF CYP2J2 IN CYCLOPHOSPHAMIDE METABOLISM Ibrahim El-Serafi Received Received
  978-P ABCB1 HAPLOTYPE IS ASSOCIATED WITH ALTERATIONS IN FUNCTIONAL ACTIVITY OF P-GP AND AFFECTS MAJOR MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH STANDARD-DOSE OF IMATINIB Douglas Vivona Received Received
  979-P DIAGNOSTIC AND THERAPEUTIC POTENTIALS OF EXPRESSION LEVELS OF BIOACTIVE SPHINGOLIPID GENES IN NEWLY DIAGNOSED AND DRUG-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS Yusuf Baran Received Received
  980-P SMO INHIBITOR SPECIFICALLY TARGETS THE HEDGEHOG PATHWAY AND REVERTS THE DRUG-RESISTANCE OF LEUKEMIC STEM CELLS viviana guadagnuolo Received Received
  983-P CHARACTERIZATION OF THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF PACRITINIB (SB1518), A NOVEL ORAL JAK2/FLT3 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS, AML AND LYMPHOMA Kristin MacIntosh Received Received
  987-P PULMONARY EFFECTS OF PERFLUOROCARBON EMULSION THERAPY ON INFECTED SICKLE CELL MICE Nawal Helmi Received Received
  988-P THE BTK-SPECIFIC INHIBITOR ONO-4059 SYNERGIZES WITH THE BCL2 INHIBITOR ABT-263. Martin Dyer Received Received
  989-P EFFICIENCY OF CD19 TARGETING BY MONOCLONAL ANTIBODIES IN EX VIVO AND MOUSE MODELS OF CHILDREN ACUTE B-LYMPHOBLASTIC LEUKEMIAS Arthur Dony Received Received
  990-P INFLUENCE OF HISTONE DEACETYLASE INHIBITORS (HDACI) ON CD20 EXPRESSION AND EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES Malgorzata Wanczyk Received Received
  991-P BOTANICAL ALKYL HYDROQUINONE HQ17(3) EXHIBITS CYTOTOXIC EFFECT ON SUP-B15 ALL CELLS HARBORING T(9;22) PHILADELPHIA CHROMOSOME THROUGH INDUCING IRON-DEPENDENT LYSOSOMAL EVENTS AND OXIDATIVE STRESS Chung-Yi Hu Received Received
  995-P THE DONOR DEPENDENT IMMUNE MODULATORY POTENTIAL OF MESENCHYMAL STROML CELL PREPARATIONS CAN BE PREDICTED BY GALECTIN-9 Christopher Ungerer Received Received
  996-P INCREASING SAFETY AND EFFICACY OF TCR TRANSFER BY EMPLOYING A MINIMALLY MURINIZED HUMAN TUMOR-REACTIVE SINGLE-CHAIN TCR Beate Hauptrock Received Received
  998-P STAINING OF ANTIGEN-SPECIFIC CD4 T CELLS USING MHC CLASS II TETRAMERS GENERATED ACCORDING TO A NOVEL METHOD OF PEPTIDE-MHC CLASS II MONOMER PRODUCTION AND PURIFICATION Peter Braendstrup Received Received
  999-P PMHC ARRAYS DEMONSTRATE THAT UNTOUCHED T CELL POPULATIONS FROM PRESENTATION ACUTE MYELOID LEUKAEMIA PATIENTS PREDOMINANTLY RECOGNIZE THE CANCER-TESTIS ANTIGEN, PASD1 Barbara Guinn Received Received
  1000-P CYTOKINE INDUCED KILLER CELLS ARE ACTIVE AGAINST NON-SMALL CELL LUNG CANCER AND OVERCOME THE ACQUIRED RESISTANCE TO TARGET THERAPIES Maja Todorovic Received Received
  1002-P NATURAL KILLER CELL EXPANSION UNDER GOOD MANUFACTURING PRACTICE CONDITIONS FOR CLINICAL USE IN ADULT PHILADELPHIA ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS Nadia Peragine Received Received
  1003-P EFFICIENT GENERATION OF HLA-A2 AND A24-RESTRICTED WT1-SPECIFIC CYTOTOXIC T LYMPHOCYTES USING GENE-ENGINEERED ARTIFICIAL ANTIGEN-PRESENTING CELLS Masahiro Ogasawara Received Received
  1004-P OPTIMIZATION OF ALLOGENEIC NK CELLS FOR ADOPTIVE TRANSFER THERAPY Michal Besser Received Received
  1007-P CENTRALIZED PRODUCTION AND DISTRIBUTION OF CMV-SPECIFIC CYTOTOXIC T CELL LYMPHOCYTES Anke Friedetzky Received Received
  1008-P LAK CELLS AND ANTI-CD20 MONOCLONAL ANTIBODIES AS INMUNOTHERAPY ON FOLLICULAR LYMPHOMA: ENCHANCED ANTIBODY-DEPENDENT CELL CITOTOXICITY OF LAK CELLS IN ASSOCIATION WITH GA101 RATHER THAN RITUXIMAB Alfonso Piérola Ana Received Received
  1009-P ROLE OF CIRCULATING &945;&946;-DOUBLE NEGATIVE T CELLS (DNT) IN LYMPHOMA PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY Giacoma De Tullio Received Received
  1010-P EFFECT OF HISTONE METHYLTRANSFERASE EZH2 INHIBITOR 3-DEAZANEPLANOCIN A (DZNEP) ON ERYTHROPOIESIS Tohru Fujiwara Received Received
  1011-P Locus Control Region in the HBB globin cluster: HS3 deletion has a very limited effect over adult globin gene expression Felix De La Fuente Received Received
  1013-P INHIBITION OF ERYTHROPOIESIS THROUGH HEPCIDIN AND ROS IN TRANSFUSION-RELATED IRON OVERLOAD MICE MASAYOSHI MASUKO Received Received
  1014-P CONGENITAL DYSERYTHROPOIETIC ANEMIA DUE TO A NOVEL GATA-1 MUTATION Janet Pereira Received Received
  1015-P EFFECTS OF CHRONIC PSYCHOLOGICAL STRESS ON EXTRAMEDULLARY ERYTHROPOIESIS: INVOLVEMENT OF EPOR, GR, C-KIT AND BMP4 SIGNALING Mirela Budec Received Received
  1016-P DOES THE OPTICAL MICROSCOPE TELL US THE COMPLETE STORY IN MEMBRANE-CYTOSKELETON DISORDERS? A STUDY OF RED BLOOD CELLS WITH ATOMIC-FORCE AND SCANNING-ELECTRON MICROSCOPES IN HEREDITARY SPHEROCYTOSIS Dimosthenis Stamopoulos Received Received
  1017-P INVESTIGATION OF HEMORHEOLOGICAL PARAMETERS AT THE DIAGNOSIS AND THE FOLLOW-UP OF NUTRITIONAL VITAMIN B12 DEFICIENT CHILDREN Hazal Tancer-Eli Received Received
  1018-P X-LINKED SIDEROBLASTIC ANEMIA: A PROMOTER MUTATION IN THE ALAS2 GENE Janet Pereira Received Received
  1022-P IMMUNOGENICITY OF LIPEGFILGRASTIM AND PEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: INTEGRATED ANALYSIS FROM PHASE II AND III STUDIES Afsaneh Abdolzade-Bavil Received Received
  1024-P LIPEGFILGRASTIM A LONG-ACTING, ONCE-PER-CYCLE, GLYCOPEGYLATED RECOMBINANT HUMAN FILGRASTIM CREATED WITH SITE-SPECIFIC GLYCOPEGYLATION TECHNOLOGY Christian Scheckermann Received Received
  1025-P SAFETY AND TOLERABILITY OF LIPEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: AN INTEGRATED ANALYSIS OF PHASE II AND III STUDIES Oleg Gladkov Received Received
  1026-P CARDIAC INVOLVEMENT IN TYPE 3 EGYPTIAN GAUCHER DISEASE PATIENTS: A REPORT OF 7 CASES AND A NEWLY REPORTED ANOMALY Magy Abdelwahab Received Received
  1027-P A FEASIBILITY STUDY OF HOME MONITORING OF BLOOD NEUTROPHIL COUNTS IN PATIENTS WITH CHRONIC NEUTROPENIA David Dale Received Received
  1029-P LANGERHANS CELL HISTEOCYTOSIS (LCH) IN EGYPTIAN CHILDREN. A SINGLE CENTER EXPERIENCE. Sedky Mohamed Sedky Received Received
  1030-P PEGFILGRASTIM AS PROPHYLAXIS OF FEBRILE NEUTROPENIA DURING CHEMOTHERAPY OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA Claudio Cerchione Received Received
  1031-P CHRONIC BENIGN NEUTROPENIA IN ADULTS: LABORATORY AND CLINICAL PARAMETERS OF A 6-YEAR FOLLOW-UP BRUNO FATTIZZO Received Received
  1034-P LANGERHANS CELL HISTIOCYTOSIS: ONE CENTER EXPERIENCE BETWEEN 1990-2012 Tulin Tiraje Celkan Received Received
  1035-P A NEW TYPE OF CHEDIAK-HIGASHI SYNDROME? CASE REPORT OF A BLACK HAIRED GIRL WITHOUT OCULOCUTANEUS ALBINISM PRESENTED WITH EARLY ONSET HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS Halil Ugur Hatipoglu Received Received
  1036-P CHEMOTHERAPY-ASSOCIATED TREATMENT BURDEN IN BREAST CANCER PATIENTS RECEIVING LIPEGFILGRASTIM OR PEGFILGRASTIM: SECONDARY EFFICACY DATA FROM A PHASE III STUDY Oleg Gladkov Received Received
  1037-P USE OF ROMIPLOSTIM IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (CITP) DURING PERI-OPERATIVE PERIOD William Alexander Received Received
  1039-P A MULTICENTER OBSERVATIONAL STUDY FOR EARLY DIAGNOSIS OF GAUCHER DISEASE IN PATIENTS WITH SPLENOMEGALY AND/OR THROMBOCYTOPENIA Irene Motta Received Received
  1040-P A RETROSPECTIVE ANALYSIS OF EPSILON-AMINO-CAPROIC ACID THERAPY IN HYPOPROLIFERATIVE THROMBCYTOPENIA Shweta Jain Received Received
  1041-P THE USE OF MYCOPHENOLATE MOFETIL IN THE TREATMENT OF CHRONIC REFRACTORY IMMUNE THROMBOCYTOPENIA PURPURA Alice Taylor Received Received
  1043-P DURATION OF BLEEDING SYMPTOMS 14 DAYS BEFORE DIAGNOSIS IS A STRONG PREDICTOR FOR DEVELOPMENT OF CHRONICITY IN CHILDHOOD PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) Andromachi Papagianni Received Received
  1044-P PLATELET ACTIVATION MARKERS IN PATIENTS WITH INCREASED CARDIOVASCULAR RISK Gavriilaki Eleni Received Received
  1046-P THROMBOCYTOPENIA PREDICT MORTALITY IN CRITICALLY ILL PATIENTS Emel Gurkan Received Received
  1049-P THE IMMATURE PLATELET FRACTION IS SENSITIVE TO THE PLATELET SIZE AND A USEFUL PARAMETER FOR SCREENING FOR MACROTHROMBOCYTOPENIA Miyazaki Koji Received Received
  1052-P OVERVIEW OF RUSSIAN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) REGISTRY Igor Lisukov Received Received
  1053-P DIFFERENTIAL DIAGNOSIS OF THROMBOTIC MICROANGIOPATHY: DATA FROM PADOVA TTP CASE SERIES Giulia Berti de Marinis Received Received
  1055-P EXTREME THROMBOCYTOSIS ( 1000 X 109 /L) IN 336 PATIENTS- REPORT OF A FOUR-YEAR EXPERIENCE Emmanouil Papadakis Received Received
  1056-P ANTIPLASMIN, BUT NOT AMILORIDE, PREVENTS SYNOVITIS AND CARTILAGE DESTRUCTION FOLLOWING HEMARTHROSIS IN HEMOPHILIC MICE laurens nieuwenhuizen Received Received
  1058-P MOLECULAR DIAGNOSTIC IN 47 UNRELATED FAMILIES WITH HAEMOPHILIA A IN ARAGON (SPAIN) Silvia Santa Catalina Received Received
  1059-P IMPAIRED PROPLATELET FORMATION IN A NOVEL GLANZMANN VARIANT MACROTHROMBOCYTOPENIA Koji Miyazaki Received Received
  1060-P MUTATION ANALYSIS IN TURKISH RARE BLOOD DISORDERS D&304;DEM TORUN Received Received
  1062-P HOW DO WE ENCOUNTER RARE FACTOR DEFICIENCIES IN CHILDREN? SINGLE CENTER RESULTS Zafer Salcioglu Received Received
  1066-P ACQUIRED VON WILLEBRAND SYNDROME AND MONOCLONAL GAMMOPATHY: CLINICAL CHARACTERIZATION AND RECOVERY TO INFUSION OF VWF-CONTAINING CONCENTRATES Chiara Ambaglio Received Received
  1067-P VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN HOSPITALIZED OBSTETRIC PATIENTS : A MULTICENTRE CROSS-SECTIONAL STUDY Maeve Crowley Received Received
  1068-P INVESTIGATION TO IMPROVE DETECTION OF LUPUS ANTICOAGULANT IN A LOCAL POPULATION EXPERIENCING RECURRENT MISCARRIAGE AND INTRAUTERINE DEATH Ailin McMahon Received Received
  1070-P THROMBOSIS IN CHILDHOOD ACUTE LEUKEMIA yaman yntem Received Received
  1072-P ULTRASTRUCTURAL ANALYSES OF THE NOVEL CHIMERIC HEMOSTATIC AGENT GENERATED VIA NANOTECHNOLOGY, ABS NANOHEMOSTAT, AT THE RENAL TISSUE LEVEL Ibrahim Haznedaroglu Received Received
  1073-P MORTALITY OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND RELATION TO COAGULATION AND INFLAMMATORY BIOMARKERS Shereef Elmoamly Received Received
  1074-P EPCR SER219GLY POLYMORPHISM AND SUSCEPTIBILITY TO VENOUS THROMBOEMBOLISM IN THE POPULATION OF NORTH-WESTERN RUSSIA Sergey Kapustin Received Received
  1075-P POLYMORPHISM OF VASCULAR TONE REGULATING GENES AND THE RISK OF VENOUS THROMBOEMBOLISM IN INDIVIDUALS WITH INHERITED THROMBOPHILIA Anastasia Polyakova Received Received
  1076-P PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN PATIENTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA A SYSTEMATIC REVIEW Mandy Lauw Received Received
  1077-P THROMBOPHILIAS INCIDENCE IN PATIENTS WITH FETAL LOSS IN LAST TRIMESTER AND EVALUATION OF THE EFFECTIVENESS OF TREATMENT LAURA BERMEJO MARTÍNEZ Received Received
  1079-P THE NOVEL NOX INHIBITOR 2-ACETYLPHENOTHIAZINE IMPAIRS COLLAGEN-DEPENDENT THROMBUS FORMATION IN A GPVI-DEPENDENT MANNER Dina Vara Received Received
  1080-P COMPARISON OF PATIENTS AND PHYSICIANS PERCEPTIONS OF PATIENTS BASELINE HEALTH-RELATED QUALITY OF LIFE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA Isabelle Vande Broek Received Received
  1081-P PROFILING PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES WHO PREFER TO RECEIVE SURVIVAL PROGNOSTIC INFORMATION. FINAL RESULTS FROM A LARGE INTERNATIONAL PROSPECTIVE COHORT OBSERVATIONAL STUDY Fabio Efficace Received Received
  1082-P CROSS-CULTURAL DEVELOPMENT OF AN EORTC QUESTIONNAIRE FOR ASSESSING QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA PATIENTS: THE EORTC QLQ-CML24 Fabio Efficace Received Received
  1084-P HOW ACCURATE ARE PHYSICIANS IN ESTIMATING SYMPTOM SEVERITY AND HEALTH STATUS OF THEIR CHRONIC MYELOID LEUKEMIA PATIENTS? Fabio Efficace Received Received
  1085-P PATTERNS OF FATIGUE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER OBSERVATIONAL STUDY Fabio Efficace Received Received
  1086-P PAIN AND EMOTIONAL DISTRESS IN HEMATOLOGIC PATIENTS THROUGHOUT ALL PHASES OF DISEASE: RESULTS FROM A MULTIDISCIPLINARY RESEARCH TEAM IN MODENA UNIVERSITY HOSPITAL Pierluigi Alfieri Received Received
  1087-P EFFICACY OF FENTANYL IN COMPARISON TO KETAMINE IN ANALGESIC EFFECT FOR HEMATOLOGY /ONCOLOGY PROCEDURES IN CHILDREN. A RANDOMIZED, DOUBLE-BLINDED, CROSSOVER, PLACEBO-CONTROLLED TRIAL chanchai traivaree Received Received
  1088-P IS SCREENING FOR MALNUTRITION USEFUL IN OLDER PATIENTS WITH AGGRESSIVE HAEMATOLOGICAL MALIGNANCIES? Anja Velghe Received Received
  1089-P IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN ACUTE MYELOID LEUKEMIA SURVIVORS Annemieke Leunis Received Received
  1090-P VALIDATION OF THE G8 IN OLDER PATIENTS WITH A HAEMATOLOGICAL MALIGNANCY Anja Velghe Received Received
  1091-P PSYCHOLOGICAL ASSESSMENT OF SIBLINGS OF PATIENTS WITH CHILDHOOD CANCER: A FORGOTTEN GROUP Ragab Iman Received Received
  1092-P HEALTH-RELATED QUALITY OF LIFE AMONG LONG-TERM SURVIVORS OF ADOLESCENT HODGKINS LYMPHOMA TREATED WITH PEDIATRIC APPROACH Sergey Semochkin Received Received
  1094-P EARLY SUPPORTIVE/PALLIATIVE CARE INTEGRATED WITH STANDARD HEMATOLOGICAL CARE (SIMULTANEOUS CARE) IN MULTIPLE MYELOMA PATIENTS FEDERICO VINCENZO Received Received
  1095-P WHAT DO PRELIMINARY ANALYSES HIGHLIGHT AS THE KEY FEARS AND WORRIES OF CHILDREN AND YOUNG PEOPLE WITH SICKLE CELL DISEASE AND WHAT CAN WE DO TO SUPPORT THEM? Florence Bristow Received Received
  1096-P COMPREHENSIVE ANALYSIS OF CLINICALLY RELEVANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN HEMATOLOGIC MALIGNANCY FROM THE VIEWPOINT OF REVISED EMAS GUIDELINE ON ANTICANCER MEDICINAL PRODUCTS Sumimasa Nagai Received Received
  1097-P DOES PREGNANCY INFLUENCE REMISSION RATE IN HEMATOLOGICAL MALIGNANCIES Maria Vinogradova Received Received
  1098-P VALIDATION OF A COMPREHENSIVE HEALTH STATUS ASSESSMENT SCALE IN OLDER PATIENTS (= 65 YEARS) WITH HEMATOLOGICAL MALIGNANCES. GAH STUDY Cristina Romera Received Received
  1099-P PSYCHOLOGICAL MORBIDITY FOLLOWING THE DIAGNOSIS OF A HAEMATOLOGICAL MALIGNANCY Barry Kevane Received Received
  1100-P QUALITY OF LIFE OF THE PATIENTS WITH HEMATOLOGICAL MALIGNANCIES LIUDMILA GRITSAY Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon - Fri 8:15 - 15:00
05:20
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

EUROPEAN HEMATOLOGY ASSOCIATION

18th Congress of EHA

 

13-16 June 2013 STOCKHOLM
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 13/06/2013 TO 16/06/2018
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.18eha.2013 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 12/06/2013
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster









PosterSessionOnline
Logo Draft
 
Logo Cert